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ABSTRACT 
Maternal nutrition during gestation has long-term effects on skeletal muscle 
development of the offspring. In this thesis, we studied the effect of energy restriction 
during late gestation on gene expression in the blood and muscle tissues of 
preconditioned beef calves. The first chapter corresponds to a literature review in which 
we describe aspects related to this research, such as muscle and immune system 
development, gene expression, and the use of RNA-seq data to answer complex 
biological questions. The second chapter describes a research project in which, 
multiparous cows were divided into two groups: cows fed 70% and 100% of their energy 
requirements during the last third of gestation. Blood and muscle samples were collected 
from the offspring, and total RNA was extracted and sequenced (RNA-seq). Finally, 
statistical analyses were performed to identify differentially expressed genes as an effect 
of maternal energy restriction, overrepresentation of related biological functions, and to 
construct gene-gene networks. A total of 160, 164, and 346 DEG (q-value < 0.05) were 
identified in the skeletal muscle for the effects of diet, sex, and diet-by-sex interaction, 
respectively. For blood, 452, 1392, and 155 DEG were identified for the effects of diet, 
time, and diet-by-time interaction, respectively. For skeletal muscle, results based on diet 
identified genes involved in the muscle metabolism.  On muscle, from the 10 most DEG 
down-regulated in the energy-restricted group (REST), we identified 6 genes associated 
with muscle metabolism and development, SLCO3A1, ATP6V0D1, SLC2A1, GPC4, 
RASD2, and SLC2A1. On blood, among the top 10 DEG, we found genes related to 
response to stress overexpressed in the REST after weaning, such as SOD3 and INO80D, 
and to immune response down-regulated in the REST after vaccination, such as OASL, 
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KLRF1, and LOC104968634. Among the DEG identified in both blood and muscle, 
including VAT1, CABLES1, SLC20A2, ILF3, and QDPR were down-regulated in the 
muscle and up-regulated in blood, and SPAG17 and LOC107131247 were down-
regulated in both. 
Therefore, the findings support the hypothesis that alterations in the intra-uterine 
environment can alter the gene expression of muscle and blood on the offspring which 
and, consequently, modify postnatal development. 
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CHAPTER 1.    LITERATURE REVIEW 
Introduction 
The deposition of skeletal muscle has significant implications for animal meat-
production systems. The number and size of muscle fibers are important to establish muscle 
mass. Muscle fibers are formed mainly during the mid-gestation, and the definitive number is 
determined before birth [1]. On the other hand, skeletal muscle fiber hypertrophy occurs in 
late gestation and continues in postnatal development [1]. In addition, the heath of the 
animals impacts performance independently of the category of the animal, since a well-
developed immune system will protect the animal from pathogens [2,3]. Moreover, immune 
system programming could give rise to changes in the fetal immune system that persists over 
the course of life [4]. 
Maternal nutrition has been pointed as one of the main factors affecting intra-uterine 
environment, delaying or enhancing fetal development [5]. The increase in nutritional 
requirements by beef cows during late gestation [6], can cause lack of nutrients for optimum 
fetal development [7]. Metabolizable energy restriction has been shown to downregulate the 
mitogenic responses of T lymphocytes from calves [8]. Thus, prenatal programming of 
physiological systems can alter the growth and function of organ systems and pathology into 
adulthood [9]. In other words, nutritional deficiency may affect the expression of genes 
regulating myogenesis and immune response in the fetus, which can have long-term effects 
on progeny development affecting the productive performance [10], and, consequently, the 
livestock industry [5]. Therefore, the last trimester of gestation is a critical period for fetal 
growth [10]. 
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The increase in size of muscle fibers continues after birth, making this phase also 
critical for proper muscle development. Preconditioning phase is a crucial period for beef 
calves, since the animals pass through stressful procedures such as vaccination, weaning, and 
diet changes [11,12]. As a response, there is a mobilization of protein from muscle [13] to 
increase the synthesis of proteins and cells involved in the immune system [14] . 
Consequently, the growth performance is compromised due to limited availability of 
nutrients to muscle development. Also during this period, there is a decrease in energy and 
protein intake [3] which can reduce innate immune system and, consequently, impact 
vaccination response [12]. 
Sequencing-based methods have been widely used to identify differentially expressed 
genes and pathways in animals under different biological conditions. Among these 
technologies, RNA-seq has several advantages, including whole transcriptome analysis, 
sensitivity for lowly expressed transcript quantification, and detection of expressed genes 
involved in specific functions (i.e., muscle development and immune response) [15].  
 
Fetal Development 
Muscle Development 
Fetal muscle development and myogenesis 
The fetal stage is especially important for skeletal muscle development because the 
muscle fibers are formed mainly during mid-gestation period, during 2 and 7 months in beef 
cattle [1], and the definitive number is determined before birth [16]. Skeletal muscle is 
composed of muscle fibers, fat cells, and connective tissue, all derived from mesenchymal 
multipotent cells; therefore, skeletal muscle development involves myogenesis, adipogenesis, 
and fibrogenesis [17]. 
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The development of skeletal muscle initiates during the embryonic stage [18]. The 
activation of Wnt pathway signaling and SHH works as signals to commit portion of the 
mesenchymal stem cells to the myogenic lineage [19]. This stimulation regulates the 
expression of paired box (Pax) 3, Pax7, and GLI1 [20]. First, Pax3 and Pax7 are expressed in 
the mesoderm, which acts upon two myogenic regulator factors (MRF), MYF-5, and MYOD-
1 [20]. As a result, the proliferating myoblasts withdrawal from cell cycle to start to 
differentiate. Concomitantly, myoblasts initiate the expression of another important MRF, 
MYOG, which is necessary for the formation of multinucleated myotubes. Primary myofibers 
are first formed in the embryonic stage, followed by the formation of secondary myofibers in 
the mid and late gestation in humans, and late and neonatal stages in mice [21]. The 
formation of secondary myofibers overlaps with adipogenesis which is initiated at mid 
gestation in humans and late gestation in rodents [16]. 
Adipogenesis is initiated around mid-gestation and peaks near parturition (Figure 1.1) 
[21]. The mechanisms controlling adipogenesis have been primarily studied in vitro by cell 
culture studies [22]. Adipogenesis is mainly controlled by Peroxisome proliferator-activated 
receptor gamma (PPARγ) and CCAAT-enhancer-binding proteins (C/EBP) [23]. The 
activation of PPARγ stimulates the transcription factors, C/EBPβ and C/EBPδ. Also, it 
stimulates C/EBPα, which promotes the differentiate phenotype [23]. 
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Figure 1.1 Density of multipotent cells and adipogenic potency of bovine skeletal muscle. The 
dates are approximate and represent the progression through the various developmental 
stages. Adipogenesis is initiated around mid-gestation in ruminant animals and peaks near 
the birth. The adipogenic potency gradually declines postnatally because of depletion of 
pluripotent cells [16]. 
 
Fibrogenesis in fetal skeletal muscle occurs mainly in mid gestation, coinciding with 
adipogenesis, although it seems to be ongoing during the whole gestation. This process is 
mainly regulated by Bone Morphogenic Proteins (BMPs), which belongs to the Transforming 
growth factor (TGF) alpha (TGF-α) super family. The regulatory Smads, Smad 1, 5 and/or 8, 
bind to the BMPs becoming activated, which associates with Smad 4 to enhance 
adipogenesis. Then this complex is translocated into the nucleus to initiate transcription of 
TGF-α target genes [24,25], including FN and COL1A1 [26]. 
Together, these three mechanisms - myogenesis, adipogenesis, fibrogenesis - produce 
the basic structure of skeletal muscle. Because most myocytes, adipocytes, and fibroblasts in 
the fetal muscle are derived from the same pool of mesenchymal stem cells, defining the 
mechanisms regulating mesenchymal stem cell differentiation in fetal muscle is essential to 
improving animal production efficiency [17]. 
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Effect of prenatal muscle growth on performance  
Alterations during fetal stage of the offspring can affect the offspring performance 
quantitatively and qualitatively (Figure 1.2). Since most of muscle fibers are formed during 
the fetal stage, limited number of fibers developed during this stage can negatively affect the 
physiological functions of the offspring, with consequences to carcass yield and production 
efficiency [27,28]. 
 
Figure 1.2 Effects of maternal nutrition on bovine fetal skeletal muscle development. The 
dates are estimated mainly based on data from studies in sheep, rodents, and humans and 
represent the progression through the various developmental stages. Nutrient restriction 
during mid-gestation reduces muscle fiber numbers, whereas restriction during late gestation 
reduces both muscle fiber sizes and the formation of intramuscular adipocytes [16]. 
 
The amount of intramuscular fat (i.e., marbling), which contributes to both meat 
flavor and texture, is determined by the number and size of intramuscular adipocytes. As 
discussed previously, both secondary muscle fibers and adipocytes are formed mainly during 
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mid gestation and are derived from the same pool of mesenchymal stem cells, generating a 
competition between them [29]. Therefore, any management alterations, such as changing 
maternal nutrition which enhances the number of mesenchymal cells committed to 
adipogenesis, will increase the number of intramuscular adipocytes and thus marbling [16]. 
This stage of fetal development is also associated with fibrogenesis, which generates the 
connective tissue [17]. This tissue is necessary for muscle development since it is part of the 
extracellular matrix; however, if in excess it is associated with toughness of the meat and, 
therefore, is not desirable [17]. 
Adipogenesis and fibrogenesis are as important as myogenesis for proper muscle 
development. Therefore, studies that aim to understand their generation and development in 
fetal skeletal muscle are imperative. 
 
Muscle fiber types 
Skeletal muscle is formed by muscle fibers, which can be classified as being red or 
white, basically based on their color intensity [30]. Also, the muscle fiber types differ about 
the speed of contraction and the type of energy metabolism in each type of fiber [31]. 
The primary function of the muscle is to contract and to create tension between two 
anatomical locations, and the function can be adjusted according to the needs of the animal 
[32]. One of the main proteins controlling the contraction is myosin whose type define the 
speed of contraction. Basically, myosin binds to actin to activate the ATPase activity and to 
promote the contraction [33]. Therefore, the classification of muscle fibers is based on the 
actomyosin ATPase activity, in which the fibers can be classified in type 1, 2A, and 2B [31]. 
In addition to the type of myosin and speed of contraction, muscle fibers can be 
classified based on the type of enzymes used to supply energy for contraction, glycolytic or 
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oxidative. Glycolytic metabolism provides an abundance of lactate dehydrogenase whereas 
oxidative provides succinate dehydrogenase, adenine dinucleotide, and tetrazolium reductase 
[34]. Adding the energy metabolism compound to the myosin type classification, add a new 
class of fiber type. So, now the fibers can be classified as type 1, 2A, 2X, and 2B [35]. 
Along with this classification, muscle fibers types differ in many characteristics, such 
as content of myoglobin, fiber diameter, fatigue resistance, number of mitochondria, lipid 
content, and glycogen content (Table 1) [35]. Oxidative red fibers contain higher amounts of 
myoglobin for oxygen storage which is compatible with the metabolism metabolizing lipid. 
Conversely, glycolytic metabolism, which predominates in white fibers, contain enzymes 
that can readily use glycogen which are consistent with their rapid contraction speed. White 
fibers work in a phasic mode of action; they contract fast in short burst, so they get easily 
fatigued. Red fibers are slower, but last for longer time, which is referred as tonic phase [35]. 
Table 1.1 Characteristic of muscle fibers in domestic meat animals 
 Type 1 Type 2A Type 2X Type 2B 
Color Red  Red Pink  Pink/white   
Contraction time Slow Moderately fast Fast Very fast 
Resistance to fatigue High Fairly high Medium Low 
Contractile action Tonic Tonic Phasic Phasic 
Mitochondrial density High High Medium Low 
Oxidative capacity High High Medium Low 
Glycolytic capacity Low Low Medium High 
Lipid content High Medium Low Low 
Glycogen content Low Low High High 
Myoglobin content High Medium Low Low 
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Muscle fibers are related to muscle development and meat quality [36]. Metabolic 
activities in normal cells rely primarily on mitochondrial oxidative phosphorylation; 
however, external interference in the normal activity may shift the metabolism to glycolytic, 
which is less efficient to produce energy [37]. Maternal nutrition may affect the amount of 
the fibers types, influencing the performance of the animal and production efficiency. Daniel 
et al. [38] showed that maternal dietary restriction during mid-gestation increases the number 
of fast (type II) muscle fibers, which generate energy through glycolytic pathways, as a 
compensatory process due to limited energy availability for muscle development. 
 
Immune System Development 
The cattle immune system begins to develop prenatally. At about 40 days of 
gestation, the thymus, a lymphoid organ that produces T cells for the immune system, is 
already evident [39]. At 70 days of gestation, it is possible to observe fetal response to some 
viruses [39]. By the third trimester, the calf can respond to many different infections. Few 
days around calving, there is an increase in the maternal and fetal steroid necessary to 
calving; however, it suppresses the immune responses of the calf [39]. At birth, the calf has 
no antibodies in the blood stream, unless infected before birth, and the immune cells 
functions are slower and lower than in adults. Since the immune response of the neonatal calf 
is still immature, it is necessary to provide adequate passive antibody transfer via colostrum. 
By the age of 5 to 8 months, the immune system has completely developed [39]. 
Few studies elucidated the immune system development prenatally in cattle and most 
of them focused on comparisons with other species. It has been shown that during 
development, cattle shared a total of 93 genes expressed by their placentae with humans. 
Most of those genes are related to immune system modulation (i.e. Chemokine receptor 
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activity and negative regulation of T cell proliferation). For example, V-set and 
immunoglobulin domain-containing 4 negatively regulated T-cell activation [40] is highly 
expressed by endometrial macrophages in the pregnant cow [41]. Another gene expressed 
during pregnancy is the PD-1, which is suggested to promote and enhance induced regulatory 
T-cells through antagonism of the mTOR cascade in naive T-cells on nonhematopoietic 
tissues [42]. 
 
Immune system and stress response  
Stress response is associated with an interaction of systems, inducing the central 
nervous system, the endocrine system, and the immune system. In general, the response of 
the immune system is a mechanism that organisms have developed to defend against 
environmental challenges. The most common theory is that stress suppresses components of 
the immune system, thus enhancing susceptibility of an animal to disease [43]. 
Stress response is controlled by the hypothalamic-sympathetic and the hypothalamic-
pituitary-adrenal (HPA) systems. Beginning with the hypothalamic-sympathetic system, 
neurons in the paraventricular nucleus of the hypothalamus cause release of catecholamines 
from the brain and the adrenal medulla [44]. Further, the HPA axis is activated, leading to 
production and secretion of corticotropin releasing factor (CRF) or corticotropin releasing 
hormone [44]. CRF activates endocrine cells in the anterior pituitary which start to synthesize 
and secrete proopiomelanocortin or its products, such as β-endorphin, adrenocorticoptropin 
hormone (ACTH), and melanocyte stimulating hormone. Pituitary ACTH have an effect on 
the adrenal cortex, where cells of the zona fasciculata secrete glucocorticoids, with cortisol 
being the primary glucocorticoid in cattle [45]. 
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Glucocorticoids are  produced under stress and have been shown to inhibit some 
components of the immune system, such as interleukin (IL) 4 (IL-4), IL-5, IL-6, IL-12, 
interferon gamma (IFNγ), and tumor necrosis factor-α [46,47] while increasing the secretion 
of other cytokines, i.e. IL-10 [47]. It seems like the inhibition of cytokines by glucocorticoids 
is a mechanism to avoid overshooting of the immune defenses. In general, proinflammatory 
cytokine synthesis are inhibited and immunosuppressive cytokines are stimulated [45]. The 
inhibition of IL-12 by glucocorticoids may cause a shift from a Th1 immune-driven response 
to a Th2 response [45]. Similar to glucocorticoids, catecholamines also inhibit IL-12 and 
stimulate IL-10 production [48]. Thus, glucocorticoids and catecholamines, through their 
effects on Th1 and Th2 cytokine secretion, may cause suppression of cellular immunity and 
cause a shift toward Th2-mediated humoral immunity [48]. 
 
Strategies to Modulate Pre- and Post-Natal Development 
Fetal Programming and Maternal Nutrition 
The early and most famous epidemiological studies in human that pointed to the 
possible importance of programming was the Dutch Famine birth cohort study based on the 
offspring of mothers exposed to famine in the Netherlands (Dutch winter famine of 1944–
1945) [49]. This historical study showed strongly impaired glucose tolerance, insulin 
resistance, and type-2 diabetes in those exposed to the famine during gestation due to under-
nutrition and uteroplacental insufficiency [49]. Therefore, there was an evidence that adverse 
intrauterine conditions may decrease birth weight and also impair development of the fetal 
endocrine pancreas, which gave rise to the “fetal origins of adult disease” based on the fetal 
programming phenomenon [50].  
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Fetal programming, also called developmental programming, is the response to a 
specific alteration to the maternal organism during pregnancy which can alter fetal 
physiological functions during fetal development, and have lasting consequences in the adult 
life [51]. 
Fetal nutrient deficiency has been associated with impaired fetal growth and 
predisposition to chronic disease such as coronary heart disease, stroke, diabetes and 
hypertension [52]. Similarly, fetal programming in livestock can cause a lack of optimal fetal 
growth affecting production efficiency [21]. 
Maternal nutrient deficiency has been noted as one of the main factors affecting fetal 
growth and development [53]. For example, cows subjected to nutrient deficiency during 
pregnancy gave birth to fatter offspring compared with control animals [54–56]. Another 
study, in which ewes received 50% (nutrient restricted) or 100% (control fed) of total 
digestible nutrients during mid gestation, the restricted group showed reduced muscle 
development and fewer secondary myofibers [57], showing long-term effects on offspring 
performance. Maternal nutrition also affected the intramuscular and visceral fat increasing 
the contents in skeletal muscle of nutrient restricted lambs [38,57]. Similar to undernutrition, 
overnutrition can also affect fetal development. Steers born from cows fed high-protein 
pasture in mid to late gestation had heavier body weights and hot carcass weights than 
control animals. Also, there was an increase in meat tenderness and 12th rib fat thickness in 
calves born from cows fed high-protein diets [58]. These results show that improving 
nutritional status of cows during mid to late gestation positively affects tenderness, adipose 
tissue deposition, and growth in steers [58]. 
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Studies have shown that the uterine environment may impact the regulation of genes 
in the offspring, and thus, affect the homeostatic regulatory mechanisms in the adult life. 
Jennings et al. [59] showed that altered energy supply during mid-gestation affects genes 
regulating fetal adipose and muscle development in cattle. For example, the Longissimus 
dorsi muscle of fetuses, collected from cows receiving 146% of the energy requirements 
from 85 to 180 days of gestation, had higher expression (P < 0.05) of Pref-1 compared with 
to those collected from cows receiving 87% of the energy requirement. The expression of 
C/EBP-β was higher (P < 0.05) in fetus of cows receiving low energy (72%) compared with 
the group receiving 87%. Similarly, Lan et al. [60] showed significant effects of the different 
maternal diets (alfalfa haylage versus corn) on the expression of genes in fetal tissue of 
sheep. The expression of IGF2R and H19 were higher in fetuses born from dams receiving 
alfalfa haylage compared to those born from dams receiving corn, probably due to the low 
amino acid content in the corn diet. These results provide evidences of association between 
maternal nutrition during pregnancy and the transcriptomic profile of fetal tissues. 
Maternal nutrition during pregnancy plays an essential role in the proper development 
of the placenta and the fetus. Therefore, a good understanding of how maternal diet can 
improve or delay this development is essential for increased production efficiency. Studying 
the response of genes to maternal over-feeding and nutrient restriction during mid-gestation 
could demonstrate how management decisions influence fetal adipose and muscle 
development. 
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Preconditioning Phase  
Preconditioning phase is the period immediately after weaning, in which the animals 
experience stressful events such as feedlot entry and vaccination, including Infectious Bovine 
Rhinotracheitis, Parainfluenza3, Bovine Viral Diarrhoea, and Bovine Respiratory Syncytial 
Virus vaccines [3]. The stress process promotes the production of proinflammatory 
cytokines, predominately IL-1, IL-6, and tumor necrosis factor in the animal, stimulating the 
hepatocytes to produce acute-phase proteins [12]. This activated immune response results in 
an increased mobilization of protein from muscle [13] to increase the synthesis of proteins 
and cells involved in the immune system [14]. Consequently, growth performance is 
compromised due to limited availability of nutrients to skeletal muscle development. Also 
during this period, beef calves may experience decreased energy and protein intake [3] which 
may reduce the immune capacity of the animal and, consequently, impacting their 
vaccination response [12]. 
Management strategies have been shown to reduce the impact of the acute-phase 
response and benefit dry matter intake, body weight gain, and production efficiency 
parameters in beef cattle [61]. Cooke et al. [11] showed that inclusion of a rumen-protected 
poly-unsaturated fatty acid (PUFA) source in preconditioning diets reduced the TNF-α 
response triggered by transport and feed yard entry, and benefited feedlot performance and 
carcass marbling of feeder steers. Therefore, PUFA supplementation during preconditioning 
might be a feasible alternative to enhance immunological and performance variables in 
feeder cattle. Also, early-weaning calves at 70 to 90 days of age has been reported to improve 
feedlot performance through reduction of plasma concentrations of acute phase proteins [62]. 
There is no doubt that the stimulation of the stress process and the immune response 
during acute phase response stimulates cytokines which disrupt the normal regulation of 
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metabolism in general, and protein turnover and amino acid metabolism [14]. However, 
management strategies have been shown to reduce the impact of the acute-phase response 
and benefit the performance of the animal [61]. 
 
Gene Expression 
Gene Expression Regulation 
Gene expression is regulated by fundamental cellular processes such as transcription, 
mRNA degradation, and translation. Each of these steps is controlled by gene-regulatory 
events. The first step of gene expression is the DNA transcription in which DNA is copied 
into RNA by the enzyme RNA polymerase. The regulation of gene expression is also related 
to the degradation of mRNA [63]. Both of these processes have been shown to be regulated 
by RNA interference or RNA silencing, which promote or impairs translation by silencing 
cytoplasmic mRNAs, either by triggering an endonuclease cleavage, or accelerating mRNA 
decapping [64]. Also, epigenetic modifications can control gene expression through cytosine 
methylation and histone modifications [65]. RNA translation corresponds to the synthesis of 
proteins directed by a mRNA template. The RNA sequence is read in three nucleotides 
“frame”, called codons, which encode for one amino acid. Translational regulation of mRNA 
is an important step in the control of gene expression [66]. This regulation can be controlled 
by the available amount of ribosomes or initiation factors [67] or, more often, by a change in 
the activity of these factors through phosphorylation or dephosphorylation [67]. 
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Epigenetic Modification 
All process in the organism, including myogenesis, adipogenesis, and fibrogenesis, 
are controlled by the expression of one or more crucial genes. Enhancing or silencing 
expression of genes is essential for maintaining the diversity of cells and cellular functions. 
This control may be accomplished through epigenetic modifications [68]. 
Epigenetic modifications refer to cytosine methylation and histone modifications and 
they are heritable [65]. Histone modification can cause stable alterations in gene expression 
[69] although it only passes for few generations [70]. Polycomb group proteins (PcG) and 
trithorax (trxG) group proteins regulate histone methylation, specifically of histone H3, 
leading to epigenetic modifications during cell differentiation [71]. PcG group proteins 
possess H3K27-specific trimethylase activity which mediates gene expression repression, 
whereas trxG complexes have H3K4 trimethylase activity which mediates activation of genes 
[68]. Several mechanisms can lead to gene silencing through DNA methylation: 1) 
recruitment of histone deacetylases, which removes histone acetylation, which increases the 
affinity between histones and DNA, inhibiting gene expression; 2) DNA methylation can 
directly interfere with the binding of transcription factors; and 3) DNA methylation leads to 
the formation of inactive chromatin structure [71]. 
Currently, indirect line of evidences supports epigenetic modification in regulating 
key genes controlling fetal muscle development (Figure 1.3). For example, maternal diet 
alters the expression of PPARs in fetal muscle through DNA methylation [72]. In another 
study, maternal cocaine administration causes epigenetic modification of a key protein kinase 
gene in rat heart [73]. In addition to the analysis of the transcriptome, Lan et al. [60] also 
studied the differential expression of imprinted genes and DNA methyltransferase genes as 
an effect of maternal diets on the expression of these genes. The methylation levels of CpG 
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islands of both IGF2R and H19 were higher in fetuses born from dams receiving alfalfa 
haylage compared with those born from dams receiving corn. Likewise, Cooney et al. [74] 
showed that maternal methyl supplements in mice increased the level of DNA methylation in 
the agouti LTR with positive effects to the health of the offspring. These results provide 
evidence of association between maternal nutrition during pregnancy and epigenomic 
alterations in the fetal tissues and, consequently in the adult life. 
 
Figure 1.3 Epigenetic modification as an effect of maternal nutrition. Maternal obesity may 
induce epigenetic modifications that alter the expression of genes involved in myogenesis and 
adipogenesis in mesenchymal stem cells [21]. 
 
RNA-seq 
Introduction to RNA-seq 
Several technologies have been used for transcriptome profiling, including 
hybridization methods, such as DNA microarrays [75,76], and sequencing-based approaches 
like SAGE (Serial Analysis of Gene Expression) [77] and MPSS (Massively Parallel 
Signature Sequencing) [78]. 
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DNA microarrays are based on the hybridization of mRNA extracted from biological 
samples to a pre-selected mRNA library, which can contain up to tens of thousands of 
various mRNA transcripts [79]. Then, the intensities of hybridization signals are read to 
obtain the expression level of each transcript. Some advantages of hybridization-based 
approaches include a significantly lower workload and relatively low cost [79]. However, 
these methods have several limitations including necessity of existing knowledge about 
genome sequence, high background levels owing to cross-hybridization, and a limited 
dynamic range of detection owing to both background and saturation of signals [80]. 
Sequencing-based methods do not require any pre-compilation of an mRNA library 
of sequences, but instead, they use restriction enzymes type, i.e. tagging enzymes, to collect 
short tags (typically 10–22 bases) from each mRNA molecule, provided a relevant 
recognition site exists for an anchoring enzyme. Then, either by sequencing long tags using 
conventional sequencer (SAGE), or by performing iterative parallel sequencing using a 
proprietary technique (MPSS), it is possible to determine the identity of a sufficiently large 
amount of tags in an efficient manner. The abundance of each mRNA transcript is assumed 
to be proportional to the count of occurrence of its representative tag. As an advantage, these 
technologies allow the identification of novel mRNAs; however, they require more advanced 
instruments that are higher cost, and more labor-intensive, only a portion of the transcript is 
analyzed, and isoforms are generally indistinguishable from each other [79]. These 
disadvantages limit the use of traditional sequencing technology in annotating the structure of 
transcriptomes. 
Recently, the development of novel high-throughput RNA sequencing method (RNA-
seq) has provided a new technique for mapping and quantifying transcriptomes. This new 
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technology offers several advantages over existing methods. First, comparing with 
hybridization-based approaches, RNA-seq is not limited to detecting transcripts that 
correspond to existing genomic sequence; it can reveal the precise location of transcription 
boundaries and also reveal sequence variations (for example, single nucleotide 
polymorphisms - SNPs) in the transcribed regions [81,82]. Relative to DNA microarrays, 
RNA-seq has very low, if any, background signal because DNA sequences can be 
unambiguously mapped to unique regions of the genome and the quantification correlates 
with the number of sequences obtained. Consequently, it has a large dynamic range of 
expression levels over which transcripts can be detected: a greater than 9,000-fold range was 
estimated in a study that analyzed 16 million mapped reads in Saccharomyces cerevisiae [83] 
and a range spanning five orders of magnitude was estimated for 40 million mouse sequence 
reads [84]. In addition, RNA-seq has also been shown to be highly accurate for quantifying 
expression levels, as determined using quantitative PCR (qPCR) [83]. It also shows high 
levels of reproducibility, for both technical and biological replicates [81,83]. 
Considering these advantages, RNA-seq is the first sequencing-based method that 
allows the entire transcriptome to be quantified with much lower cost than either tiling arrays 
or large-scale Sanger expressed sequencing tag. On the other hand, like other high-
throughput sequencing technologies, RNA-seq also faces several informatics challenges, 
including the development of efficient methods to store, retrieve and process large amounts 
of data [85]. The advance of technology and the development of new sequencing platforms 
are decreasing the costs of sequencing, allowing RNA-seq to replace microarrays for many 
applications that involve determining the structure and dynamics of the transcriptome. 
 
19 
Processing RNA-seq Data 
RNA-seq uses a recently developed deep-sequencing technologies. In general, a 
population of RNA (total or fragmented) is converted to a library of cDNA fragments. Then, 
adaptors are attached to one or both ends for amplification. [85]. Next, each molecule, with 
or without amplification, is sequenced in a high-throughput manner to obtain short sequences 
from single-end (SE) sequencing or both ends (paired-end; PE) sequencing [85]. The reads 
range between 30–400 base pairs (bp), depending on the DNA-sequencing technology used. 
Depending on the genome availability for the organism being studied and the research goal, 
the reads obtained from the sequencing process are either aligned to a reference genome or 
reference transcripts, or assembled de novo. 
For large transcriptomes, alignment is complicated because a significant portion of 
sequence reads matches multiple locations in the genome. In case of low-copy repetitive 
sequences, it is possible to overcome this issue assigning these multi-matched reads by 
proportionally assigning them based on the number of reads mapped to their neighboring 
unique sequences [81,84]. However, short reads with high copy numbers and long stretches 
of repetitive regions represent a greater challenge. One strategy would be to employ paired-
end sequencing, in which short sequences are determined from both ends of a DNA fragment 
[86–88] and extend the mapped fragment length to 200–500 bp. 
There are many RNA-seq protocols and analyses available and there is no optimal 
pipeline for all experiments. Every RNA-seq experimental scenario could potentially have 
different optimal methods for transcript quantification, normalization, and differential 
expression analysis [89]. 
To start with, it is important that the experimental design for the RNA-extraction 
protocol being used remove the highly abundant ribosomal RNA (rRNA), which typically 
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constitutes over 90% of total RNA in the cell, leaving the 1–2% comprising messenger RNA 
(mRNA) that we are normally interested in [90]. For this, there are two options: 1) to enrich 
for mRNA using poly(A) selection or 2) to deplete rRNA. 
Furthermore, sequencing can involve SE or PE reads. The best sequencing option 
depends on the analysis goals. PE reads are preferable for de novo transcript discovery or 
isoform expression analysis [91,92]. The cheaper, short SE reads are normally sufficient for 
studies of gene expression levels in well-annotated organisms [90]. 
Finally, a crucial design factor is the number of replicates. The number of replicates 
that should be included in a RNA-seq experiment depends on several factors, for example, 
the amount of technical variability in the RNA-seq procedures, the biological variability of 
the system under study, and the desired statistical power [90]. 
 
Quality control and trimming  
Before starting the alignment process of raw reads in the genome, it is necessary to 
analyze the quality of the reads that were generated from sequencing. This quality control 
involves the analysis of sequence quality, GC content, the presence of adaptors, 
overrepresented k-mers and duplicated reads in order to detect sequencing errors, PCR 
artifacts or contaminats [90]. 
Acceptable duplication, k-mer, and GC content levels depend on the experiment and 
the organism being studied, but these values should be homogeneous for samples in the same 
experiments. Also, it is recommended that outliers with over 30% disagreement be discarded. 
In general, read quality decreases towards the 3’ end of reads, and if it becomes too low, 
bases should be removed to improve alignment [90]. 
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FastQC [93] is a popular tool to perform quality control on Illumina reads, whereas 
NGSQC [94] can be applied to any platform. FastQC imports data from BAM, SAM or 
FastQ files and provides a quick overview to tell you in which areas there may be problems. 
The results are summarized in graphs and tables to quickly assess your data and can be 
exported to an HTML based permanent report. 
In case of low quality, software tools such as the FASTX-Toolkit [FASTX-Toolkit. 
http://hannonlab.cshl.edu/fastx_toolkit/] and Trimmomatic [95] can be used to discard low-
quality reads, trim adaptor sequences, and eliminate poor-quality bases. In addition, the 
online website PrinSeq (https://sourceforge.net/projects/prinseq/) allows us to filter, reformat, 
or trim genomic and metagenomic sequence data. It generates summary statistics of 
sequences in graphical and tabular format, providing a user-friendly interface. Sequence data 
can be filtered to remove sequence copies, sequences with N's, and low-quality sequences. 
 
Identification of transcripts  
When a reference genome is available, RNA-seq analysis will normally involve the 
mapping of the reads onto the reference genome or transcriptome to infer which transcripts 
are expressed. Mapping the reads to known genome or transcriptome focuses the analysis on 
quantification only. On the other hand, if the organism does not have a sequenced genome, 
then the analysis is based on assembling reads into longer contigs and treating these contigs 
as the expressed transcriptome. Then, the reads are mapped again to the de novo 
transcriptome for quantification. In either case, read coverage can be used to quantify 
transcript expression level [90]. 
Reads may be assigned to only one position in the reference or multi-mapped (i.e 
multireads). Multireads occur due to repetitive sequences or shared domains of paralogous 
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genes. They normally account for a significant fraction of the mapping output and should not 
be discarded. It is even more common if the reads are being mapped to the transcriptome 
because a read that would have been uniquely mapped on the genome would map equally 
well to all gene isoforms in the transcriptome that share the exon. In both cases, genome and 
transcriptome mapping, transcript identification and quantification become important 
challenges for alternatively spliced genes [90]. 
Mapping to a reference genome allows for the identification of novel genes or 
transcripts and requires the use of a gapped or spliced read mapper as reads may span splice 
junctions. The challenge is to identify splice junctions correctly, especially when sequencing 
errors occur, differences within the reference exist or when non-canonical junctions and 
fusion transcripts are sought. TopHat is one of the most popular RNA-seq mappers and 
follows a two-step strategy: 1) unspliced reads are first mapped to exons, and then 2) 
unmapped reads are split and aligned independently to identify exon junctions [96,97]. 
Many mappers exist that are optimized for different functions. For example, there are 
mappers specialized in identifying SNPs (i.e. GSNAP [98], PALMapper [99], and MapSplice 
[85]), detecting non-canonical splice junctions (i.e. STAR [100] and MapSplice [85]), and 
achieving ultra-fast mapping (i.e. GEM [101], and to map long-reads, i.e. STAR [100]). All 
of these aligners are called splice-aware aligners since they would not to try to align RNA-
seq reads to introns and identify possible downstream exons and try to align to those instead, 
ignoring introns altogether. However, if the transcriptome annotation is comprehensive, it is 
possible to choose to map directly to a FASTA-format file of all transcript sequences for all 
genes of interests. In this case, no gapped alignment is needed and unspliced mappers such as 
Bowtie [96] can be used. 
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It is important to consider some parameters during alignment, such as the number of 
mismatches to accept, the length and type of reads (SE or PE), and the length of sequenced 
fragments during mapping. 
 
Quantification 
The most common application of RNA-seq is to estimate gene and transcript 
expression. This application is primarily based on the number of reads that map to each 
transcript sequences. The simplest approach to quantification is to aggregate raw counts of 
mapped reads using programs such as HTSeq-count [102] or featureCounts [103]. This gene-
level (rather than transcript-level) quantification approach utilizes a gene transfer format 
(GTF) file containing the genome coordinates of exons and genes, and often discards 
multireads. Raw read counts alone are not sufficient to compare expression level among 
samples, as these values are affected by factors such as transcript length and total number of 
reads sequenced. [90]. 
Correcting for gene length is not necessary when comparing changes in gene 
expression within the same gene across samples, but it is necessary for correctly ranking 
gene expression levels within the sample to account for the fact that longer genes accumulate 
more reads. Furthermore, programs such as Cufflinks that estimate gene length from the data 
can find significant differences in gene length between samples that cannot be ignored [90]. 
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Statistical Analysis of RNA-seq Data 
Normalization of the Data 
Differential expression analysis requires that gene expression values be compared 
among samples [90]. The normalization of the data is important to account for the 
sequencing depth and the number of transcripts, which can differ significantly between 
samples [104]. Also, the number of fragments expected to map to a gene depends on the 
composition of the RNA population. For example, if many reads are being mapped to only 
one gene or one gene is highly expressed in one experimental condition, the remaining genes 
will be underestimated; therefore, we need to account for this difference [90]. Most 
normalization methods use the raw data to estimate appropriate scaling factors that can be 
used in downstream statistical analysis procedures, thus accounting for the sampling 
properties of RNA-seq data [89]. 
Many normalization methods have been described to deal with RNA-seq data. The 
differences among them is regarding the type of bias adjustment and the statistical strategy 
adopted. Some examples of normalization methods are: Trimmed Mean of M values (TMM) 
[105], DESeq [106], Upper Quartile (UQ) [107], Median (Med) [107], and Reads Per 
Kilobase per Million mapped reads (RPKM) normalization [84]. The normalization methods 
can be divided into two groups based on the library size concept (TMM and DESeq), or on 
the distribution adjustment of read counts (UQ, Med, RPKM). 
The TMM normalization method [105] is based on the hypothesis that most genes are 
not differentially expressed. This method is implemented in the TCC Bioconductor package 
(version 1. 0. 143) [108]. Normalization factors are calculated by selecting one sample as a 
reference and calculating the TMM factor for each non-reference sample [89]. In this 
method, it is not possible to directly estimate the total RNA production since the expression 
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levels and true lengths of every gene are unknown. However, the relative RNA production of 
two samples, i and j, can be determined by:  
𝑓" = 	 𝑆"&𝑆"' 
where fk is the relative RNA production in library k and Sk is the total RNA production. The 
TMM method uses a weighted trimmed mean of the log expression ratios to the ratio of RNA 
production. For example, for sequencing data, the gene-wise log fold changes (M value) is 
defined:  
𝑀) = 	 𝑙𝑜𝑔-	 	 𝑌)"&/𝑁"&𝑌)"'/𝑁"' 
where Mg is the M value of gene g; Ygk is the observed count for gene g; and Nk is the total 
number of reads for library k. The absolute expression levels (A value) is defined: 
𝐴) = 	1 2	𝑙𝑜𝑔- 𝑌)"&𝑁"& ∗ 𝑌)"'𝑁"' 	 
Before taking the weighted average, both values are trimmed. Precision (inverse of 
the variance) weights are used to account for the fact that log fold changes from genes with 
larger read counts have lower variance on the logarithm scale. Normalization factors across 
several samples can be calculated by selecting one sample as a reference and calculating the 
TMM factor for each non-reference sample. The TMM normalization factors can be built 
into the statistical model used to test for DEG. For example, a Poisson or negative binomial 
model would utilize an effective library size to adjust the modeled mean. It can be done using 
an additional offset in a generalized linear model. 
The DESeq normalization method [102] is also based on the hypothesis that most 
genes are not differentially expressed and is included in the DESeq Bioconductor package 
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(version 1.6.0) [102]. A DESeq scaling factor for a given lane is computed as the median of 
the ratio for each gene of its read count over its geometric mean across all lanes. The 
underlying idea is that non-DEG should have similar read counts across samples, leading to a 
ratio of 1. Assuming that most genes are not differentially expressed, the median of this ratio 
for the lane provides an estimate of the correction factor that should be applied to all read 
counts of this lane to fulfill the hypothesis. In the UQ normalization method, the gene counts 
are divided by the upper quantile of counts associated with their lane and multiplied by the 
mean total count across all the samples of the dataset [106]. The Med method is similar to 
UQ, but the counts are divided by the median counts different from 0 in the computation of 
the normalization factors. Lastly, the RPKM combines between- and within-sample 
normalization, as it re-scales gene counts to correct for differences in both library sizes and 
gene length [84]. However, it has been shown that this method may introduce bias in the per-
gene variances, especially for lowly expressed genes [109]. Normalization is an essential step 
in the analysis of gene expression [105,106] and many methods are available for this 
purpose. 
 
Differential Expression 
High-throughput sequencing of RNA fragments has been used with the purpose of 
quantifying gene expression. In general, reads obtained from sequencing are mapped to a 
target genome classified in target transcript, in the case of RNA-seq. The read count has been 
found to be – to good approximation – linearly related to the abundance of the target 
transcripts [84], which represents an important summary statistic of the number of reads 
aligned to a gene or transcript. 
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In general, RNA-seq analysis involves a very large number of genes to be tested, a 
small number of biological samples due to costs restrictions, and technical and biological 
variances which makes it a challenge to model the data [102]. One of the main interest of 
sequencing is to compare read counts between different biological conditions. To achieve 
this goal, statistical tests are used to test if an observed difference in read counts is 
significant, that is, whether it is greater than what would be expected just due to natural 
random variation. Among the statistical models used for this purpose, models assuming 
Poisson and negative binomial distributions have been widely used [85,110]. 
The Poisson distribution has the advantage of being simple, since it has only one 
parameter, where the variance of the model is equal to the mean [102]. Therefore, it can only 
account for the technical noise in RNA-seq data, predicting small variances (Figure 1.4) 
[111]. 
 
Figure 1.4 Relationship between mean and variance of RNA-seq data using Poisson 
regression. Each point represents simulated data for one biological replicate. The red line is 
the variance implied by the Poisson distribution [112]. 
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The assumption of genes having the same mean and variance is too restrictive. In 
RNA-seq data, the variance is generally greater than the mean, a phenomenon called 
overdispersion which result in a lack of control of type-I error (the probability of false 
discoveries). To address this issue, it has been proposed the model count data with negative 
binomial (NB) distributions [113] as an alternative which includes an additional dispersion 
parameter. 
 
Negative Binomial Model 
Negative binomial models have been used as an alternative approach when 
overdispersion occurs with Poisson generalized linear models [114]. The NB distribution has 
two parameters, encoding the mean and the dispersion, which allows the modeling of more 
general mean–variance relationships [102]. Anders and Huber [102] plotted the variance 
against the mean for the NB and Poisson using RNA-seq data, and showed that the NB 
model presented a better fit (Figure 1.5). 
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Figure 1.5 Comparison of the relationship between mean and variance of RNA-seq data 
using Poisson vs NB regression. Dependence of the variance on the mean for one condition 
in RNA-seq data. The scatter plot shows the transformed values to a common-scale sample 
count data of the variance plotted against the transformed values of the mean. The orange 
line is the fit variance-mean dependence by DeSeq (NB approach). The purple lines show the 
variance implied by the Poisson distribution for each of the two samples. The dashed orange 
line is the variance estimate used by edgeR (NB approach) [102]. 
 
Using a mix of a Poisson process with a gamma distribution for the Poisson 
parameter results in a distribution which is over dispersed relative to the Poisson [114]. For a 
given Poisson distribution Y with mean λ, λ follows a gamma distribution, G(k, µ) with 
probability density function [114]: 
𝑓 λ; k, µ = 	 (𝑘/µ)"𝛤(𝑘) exp −kλµ λ"BC,								λ	 ≥ 0	 
and 𝐸 λ = 	µ and 𝑉𝑎𝑟 λ = 	 JK" , where k describes the shape of the distribution. The density 
is skewed to the right and the degree of skewness decreases as k increases [114]. 
Marginally, the gamma mixture of the Poisson generates the NB distribution for Y 
[115], with probability mass function: 
𝑝 𝑦; 𝑘, µ = 	 𝛤(𝑦 + 𝑘)𝛤(𝑘)𝛤(𝑦 + 1)	 𝑘µ + 𝑘 "		 1 −	 𝑘µ + 𝑘 O		 ,				𝑦 = 0, 1, 2, … 
The dispersion parameter ɣ = 	1 𝑘, and 𝐸 𝑌 = 	µ	 and 𝑉𝑎𝑟 𝑌 = 	µ + 	ɣµ-. As ɣ 
goes to 0, the variance approximates to the mean, and it becomes a Poisson distribution 
[114]. 
The NB model for count data allows µ to depend on explanatory variables. On the 
other hand, ɣ is usually equal for all observations and correspond to the coefficient of 
variation in the gamma distribution [114]: 𝑣𝑎𝑟 𝜆𝐸(𝜆) = 	 ɣ 
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False Discovery Rate (FDR) 
The FDR procedure was described by Yoav Benjamini and Yosef Hochberg in 1995 
with the purpose of controlling type-I error (probability of false rejecting null hypotheses) in 
multiple comparison procedures [116]. By definition, the P-value is the probability of finding 
a result equal to or more extreme than what was actually observed when the null hypothesis 
of a study question is true. Similarly, in multiple testing, we can use the adjusted P-value (q-
value) to define the level in which the multiple testing procedure would reject the hypothesis 
[117]. Therefore, the multiple testing problem can be overcome by adjusting the P-values 
(Figure 1.6). 
 
Figure 1.6 Relationship between raw and adjusted p-values (q-value). Each dot represents 
the test for the effect of diet (restricted versus control) in the muscle tissue described in 
Chapter 2. 
 
To calculate adjusted P-values, it is necessary to sort P-values in ascending order, 
such as P-value1, P-value2, …, P-valuem, considering m multiple tests, where the 1st P-value 
is the smallest and the mth the largest. Then, each P-value is multiplied by an adjustment 
factor, given by 𝑎& = 	𝑚 𝑖 being i the position of the P-value (P). Then, the q-value [117] is 
given by: 
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𝑞 − 𝑣𝑎𝑙𝑢𝑒 = 	𝑎& ∗ 	𝑃&	 
In case the multiplication in this step results in a smaller q-value than what was 
obtained for the previous P-value, the previous q-value will be substituted by the smallest q-
value [117]. 
 
Covariance Structures 
Comparative experiments with repeated measures consist of samples collected in a 
longitudinal study in which measurements from each subject are made at multiple time points 
or under different conditions. Measures on the same subject at different times (or different 
conditions) may be correlated, with measures taken close together in time being more highly 
correlated than measures taken far apart in time. Therefore, it is important to account for the 
covariance structure of the data, which usually reflects a series of measurements collected 
over time. Different subjects are often assumed independent, although this assumption 
depends on the study design. Several covariance approaches are available in the literature 
[118]. 
Considering Yij the response on subject j in group i, the simple (SIM) or uncorrelated 
structure specifies that observations (Y) are independent, even on the same subject, 
satisfying: 𝑉𝑎𝑟 𝑌&'" = 	σ[\]-  𝑐𝑜𝑣 𝑌&'"_, 𝑌&'"K = 	0 
where k corresponds to different times in which a measurement was taken on the same 
subject. In this covariance structure, homogeneous variance is assumed for all observations, 
such that	𝑉𝑎𝑟 𝑌&'" = 	σ[\]-  [118]. 
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A traditional covariance structure used in repeated records is the compound 
symmetric (CS), which specifies that observations on the same individual have homogeneous 
variance and covariance, such that: 𝑉𝑎𝑟 𝑌&'" = 	σ`[,a	- +	σ`[,b	-  𝑐𝑜𝑣 𝑌&'"_, 𝑌&'"K = σ`[,a	- 	 
where σ`[,a	-  and σ`[,b	-  are the between-subjects and within subject variances, respectively. In 
the case of repeated measures across time using CS, the correlation between measurements 
does not depend on the length of the time interval between measurements, and is equal to the 
between-subjects variance [118]. Assuming three measurements on the same subject, the CS 
(co)variance matrix can be written as:  	 𝜎`[,a- +	𝜎`[,b- 𝜎`[,a- 𝜎`[,a-𝜎`[,a- 𝜎`[,a- + 𝜎`[,b- 𝜎`[,a-𝜎`[,a- 𝜎`[,a- 𝜎`[,a- + 𝜎`[,b-  
 
The first-order autoregressive (AR[1]) covariance structure specifies a homogeneous 
variance for all measures, whereas the covariance between two observations on the same 
subject depends on the length of the time interval between measurements, in way that it 
decreases as measures are taken further apart, such as: 𝑉𝑎𝑟 𝑌&'" = 	σde(C)	-  𝑐𝑜𝑣 𝑌&'"_, 𝑌&'"K = σde C 	- 	rde(C)|g	Bh| 
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where ρ represents the correlation between the measurements k1 and k2 [118] and l and m are 
the (m, l)th element of the matrix. Assuming three measures taken over time, the (co)variance 
matrix can be represented by:  
σde C- 1 rde Cg	B	h rde Cg	B	hrde Cg	B	h 1 rde Cg	B	h
rde Cg	B	h rde Cg	B	h 1  
 
Functional Analysis 
Functional analyses are primarily designed to handle a gene list data from any 
genome-wide experiments and associate the genes to annotated biological functions or 
pathways. Statistical overrepresentation tests are based the simple binomial model [119], in 
which a test gene list uploaded by the user (i.e. DEG from RNA-seq experiments, or list of 
genes with significant P-values from genome-wide association experiment), is compared to a 
reference gene list to determines whether a particular class (i.e. a Gene Ontology (GO) 
biological process) of genes is overrepresented or underrepresented [120]. 
The input (or test) list correspond to the list of genes and it is divided into groups 
based on GO classification i.e. molecular function, biological process, and KEGG pathway. 
Then, the list is compared to a reference list respective to the species of interest which is also 
divided into groups in the same way. Next, a binomial test is applied for each functional 
category (for example, protein kinase for molecular function, cell proliferation for biological 
process or apoptosis signaling pathway for pathway) to determine whether there is a 
statistical overrepresentation or underrepresentation of the genes in the test list relative to the 
reference list. For that, the reference genome has a number of expected genes associated with 
each category. Based on this number, it is possible to calculate the number of genes that 
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would be expected to be present in the test list for each category. This expected number is 
compared with the number of genes observed in the list of genes provided. When there are 
more observed than expected genes, there is an overrepresentation of genes involved in the 
specific function under investigation. If fewer genes are observed than expected, there is an 
underrepresentation [120]. 
It is necessary to test if the over- or underrepresentation is occurring by random 
chance, which can be evaluated based on a P-value from a binomial test. The ‘null’ 
hypothesis assumes that genes in the test list are sampled from the same general population 
as genes from the reference set, and thus the probability P(C) of observing a gene from a 
particular category C in the test list is the same as in the reference list [120]. First, for the 
reference list, the probability P(C) is  
𝑃 𝐶 = 	𝑛(𝐶)𝑁  
where n(C) is the number of genes mapped to category C, and N is the total number of genes 
in the reference set. Under the null hypothesis, the number of genes mapped to C in the test 
list, k(C), is distributed binomially with probability parameter P(C), and thus the P-value 
would be 
𝑃 − 𝑣𝑎𝑙𝑢𝑒 = 	 𝐾𝑘 	𝑃 𝐶 "(1 − 𝑃 𝐶 )lB" 
where K is the total number of genes in the test list and k is the number of genes in a specific 
category. Finally, a P-value cutoff is used to determine overrepresentation, i.e. when the 
number of observed genes k(C) is greater than expected P(C), or underrepresentation, i.e. 
when k(C) is smaller than P(C) [120]. 
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Construction of Genes Networks 
A network can be used for visualization of statistical information such as correlation 
matrix in which each variable, i.e. gene, is a node and each correlation an edge [121]. Thus, a 
gene-gene network constructed by correlation between the expression levels of genes may 
include hundreds to thousands of correlation estimates. The most common type of correlation 
is the Pearson’s correlation coefficient, which compares two ratio variables. The Pearson’s 
correlation coefficient (ρ) between two random variables (i and j), can be defined as [122]: 
 𝜌&' = 	 nop(&,')sq∗sr 	  where  −1	 ≤ 	𝜌&' 	≤ 1 
 
 
This correlation coefficient reveals the strength of the linear relationship between the 
two random variables. So, if ρij = 0, then i and j are said to be uncorrelated. The closer the 
value of |ρ| is to 1, the stronger is the correlation between the two variables [122]. 
Biologically, the expression of a given gene may be a function of the activity of 
several other genes. In this case, the correlation between the expression levels of a pair of 
genes must be accounted for by the expression levels of other genes. In this case, we may use 
partial correlation coefficients to construct gene networks. The partial correlation (ω) 
between two random variables (i and j) given another random variable, namely z (wij,z), can 
be obtained by [121]: ω&',u = 	 𝜌&' −	𝜌&u𝜌'u(1 −	𝜌&u- )(1 −	𝜌'u- ) 
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Partial correlation indicates correlation between two variables disregarding the effects 
of another variable, or several other variables, on this relationship [121]. For example, in an 
experiment with two treatments and in which the goal is to construct a partial correlation for 
the 10 most DEG, the partial correlation matrix may be constructed based on the difference 
of expression between the two treatments.  
Partial correlation networks are being used to represent gene co-expression networks. 
In these gene networks, each gene is represented as a node and is connected to each other 
with a line called an edge. The strength of the correlation can be represented by the thickness 
of the edge. The gene networks help to identify co-expressed (or connected) genes which can 
be used to explain patterns seen across experimental conditions. For example, Kogelman et. 
al [123] applied a weighted gene co-expression network analysis to detect clusters of highly 
co-expressed genes involved in transcriptional regulations of obesity from RNA-seq data in 
pig adipose tissue.  
 
Final Remarks 
Alterations in the maternal nutrition during pregnancy affect the intra-uterine 
environment, delaying or enhancing fetal development. Specially in late gestation, when 
there is an increase in the nutritional requirements by beef cows, a restriction in the maternal 
diet cause a lack of nutrients for optimum fetal development. This nutrient deficiency during 
the fetus development may affect the regulation of genes associated with muscle 
development and immune system in the progeny, affecting its post-natal performance. 
Therefore, we hypothesize that maternal energy restriction would cause changes in the 
expression of genes related to muscle development and immune response in the muscle and 
blood of beef calves born from cows with contrasting levels of dietary energy the last 40 days 
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of gestation. In the following chapter, we will describe a study in which we have used RNA-
seq data to identify differentially expressed genes between the control (100% of the energy 
requirements) and restricted (70% of the energy requirement) groups. The biological 
functions and relationships of the differentially expressed genes identified from this analysis 
were further explored using enrichment analysis and gene-gene networks were constructed. 
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Abstract  
Background  
Maternal nutrition has been identified as one of the main factors affecting intra-
uterine environment. Nutritional deficiency may impact the regulation of genes associated 
with myogenesis and immune response in the fetus. The increase in nutritional requirements 
by beef cows during late gestation can cause a lack of nutrients for optimum fetal 
development. Forty days before the expected calving date, cows were randomly assigned to 
one of two isonitrogenous diets: 100% (control group) or 70% (restricted group) of the daily 
net energy requirement. Muscle samples were collected at 21 days post-weaning (dpw) from 
12 heifers and 12 steers, and blood samples were collected at 0, 3, 6, and 15 dpw (12 steers). 
The objective of this work was to identify and assess the biological relevance of differentially 
expressed genes (DEG) in skeletal muscle and blood of beef calves born from cows that 
experienced 30% energy restriction during the last 40 days of gestation compare to 
unrestricted controls.  
 
Results 
A total of 160, 164, and 346 DEG (q-value < 0.05) were identified in the skeletal 
muscle for the effects of diet, sex, and diet-by-sex interaction, respectively. For blood, 452, 
1392, and 155 DEG were identified for the effects of diet, time, and diet-by-time interaction, 
respectively. For skeletal muscle, results based on diet identified genes involved in the 
muscle metabolism. In muscle, the 10 most down-regulated DEG in the energy-restricted 
group (REST), included 5 genes associated with muscle metabolism and development: 
SLCO3A1, ATP6V0D1, SLC2A1, GPC4, and RASD2. On blood, among the top 10 DEG, we 
identified genes up-regulated in the REST after weaning related to response to stress, such as 
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SOD3 and INO80D, and down-regulated in the REST after vaccination related to immune 
response, such as OASL, KLRF1, and LOC104968634. Among the DEG identified in both 
blood and muscle, VAT1, CABLES1, SLC20A2, ILF3, and QDPR were down-regulated in the 
muscle and up-regulated in blood, and SPAG17 and LOC107131247 were down-regulated in 
both. 
 
Conclusion 
In conclusion, maternal energy restriction during late gestation may limit the 
expression of genes in the muscle and increase expression in the blood of the calves. In 
addition, enrichment analysis showed that a short-term maternal energy restriction during 
pregnancy affects the expression of genes related to muscle carbohydrate metabolic process, 
and muscle contraction in muscle, as well as immunity and stress response in the blood. 
Therefore, alterations in the intra-uterine environment can modify prenatal development with 
lasting consequences through adult life. 
Keywords: RNA-seq, fetal development, fetal programming, gene expression  
 
Background 
Maternal nutrition has been identified as one of the main factors affecting intra-
uterine environment [1]. There is an increase in nutritional requirements of beef cows during 
late gestation [2], and if not met, the limited amount of nutrients available for optimum fetal 
development may affect prenatal physiological functions and, consequently, result in 
impaired post-natal growth and performance of the offspring [3,4]. Therefore, the last 
trimester of gestation is a critical period for fetal growth [3]. 
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Metabolizable energy restriction has been shown to down-regulate the mitogenic 
responses of T lymphocytes in beef calves [4]. Prenatal programming of physiological 
systems can alter the growth and function of organs and pathology into adulthood [5]. In 
other words, nutritional deficiency may impact the regulation of genes associated with 
myogenesis and immune response in the fetus, which can have long-term effects on progeny 
growth performance [3]. 
The deposition of skeletal muscle has significant implications to the animal meat-
production systems. Muscle fibers are formed mainly during mid-gestation, and the definitive 
number of fibers is determined before birth [6]. On the other hand, fiber hypertrophy occurs 
during late gestation and continues following birth [6]. In addition, since a well-developed 
immune system protects the animal from pathogens and other stressors, healthy animals 
present better performance compared to immune compromised animals during the growth 
and development [7]. Moreover, the prenatal programming of the immune system would give 
rise to changes that persist over the course of the animal’s life [8]. 
Transcriptome studies have shown changes in fetal growth and immune factors, 
especially during the final trimester of gestation. Previous studies have reported differentially 
expressed genes (DEG) in the muscle of fetuses as an effect of maternal diet during 
pregnancy based on different energy sources, which ultimately change the metabolalizable 
energy intake [9,10]. For example, decrease in expression of genes involved in muscle 
synthesis and differentiation, tissue and organ development, chromatin biology, and 
metabolic processes have been reported in calves as an effect of maternal diet during 
pregnancy based on corn compared with a diet based on alfalfa haylage, and dried corn 
distillers grains [9]. In addition, O’Loughlin et al. [11] identified DEG involved in cytokine 
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signaling, transmembrane transport, hemostasis and G-protein-coupled receptor signaling as 
a response to weaning stress in calves.  
The preconditioning phase is a critical period for beef calves, since animals pass 
through stressful processes such as vaccination, weaning, and diet changes [12,13]. As a 
response, there is a mobilization of protein from muscle [14] to increase the synthesis of 
proteins and cells involved in the immune system [15]. Consequently, growth performance is 
compromised due to limited availability of nutrients for skeletal muscle development. Also 
during this period, there is a decrease in energy and protein intake [16], which may reduce 
the immune capacity of the animal and, consequently, impact vaccination response [13]. 
We hypothesized that maternal energy restriction would cause changes in the 
expression of genes related to muscle development and immune response in preconditioned 
beef calves born from cows that experienced short-term energy restriction (30% of total 
energy requirements) during the last 40 d of gestation compared to unrestricted controls. 
Therefore, the objectives of this work were to (1) identify DEG in the muscle and blood of 
beef calves born from cows with and without energy restriction, (2) to assess the biological 
relevance of DEG, and (3) to investigate the relationships of DEG through gene networks. 
 
Materials and methods 
Animals and Diets  
Thirty recipients multiparous, nonlactating, pregnant spring-calving Angus cows with 
average body weight 631 ± 15 kg, 5.2 ± 0.98 years of age, and body condition score of 6.3 ± 
0.12 were used in this study. Cows were sired by two sires, and forty days before the 
expected calving date, cows were randomly assigned to one of two isonitrogenous diets: the 
control group (CTRL) and the restricted group (REST). Animals received total-mixed diets 
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formulated to provide 100% (CTRL) or 70% (REST) of the daily net energy requirement for 
maintenance of a 630 kg beef cow at 8 months of gestation [17]. Animals were randomly 
assigned to pens according to the treatment (n = 5 pens/treatment). Immediately after calving, 
cow–calf pairs were transferred to 1 of 6 tall fescue pastures with free choice access to water 
and a complete mineral mix. Cows received dietary treatments for 40 ± 5.08 days. All male 
calves were castrated by banding immediately after birth. Cows and calves were managed as 
a single group and rotated among pastures monthly from calving until weaning 
(approximately 227 days of age). From weaning (day 0) until 40 days post weaning (dpw), 
calves were assigned to a preconditioning period. Additional detailed information regarding 
the nutritional information of the diets, feeding strategies, and the design of the study have 
been previously described in Moriel et al. [18] . 
 
Preconditioning 
At weaning (0 dpw), calves were individually treated with doramectin for internal and 
external parasites (5 mL subcutaneous; Dectomax injectable; Zoetis Inc., Kalamazoo, MI). 
At 8 dpw, calves were vaccinated against infectious bovine rhinotracheitis virus, bovine viral 
diarrhea virus types 1a and 2, parainfuenza 3 virus, Mannheimia haemolytica (2 mL 
subcutaneous; Bovi Shield Gold One Shot; Zoetis Inc.), and Clostridium spp. (2 mL 
subcutaneous; Ultrabac 7; Zoetis Inc.). At 21 dpw, calves received 2 mL subcutaneous 
boosters of Bovi Shield Gold 5 (Zoetis Inc.) and Ultrabac 7. This vaccination protocol was 
used to replicate the standard protocol used by the local preconditioning alliance (Mountain 
Cattle Alliance, Canton, NC) [19,20]. 
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Tissue Collection 
At 21 dpw, a biopsy of the skeletal muscle Longissimus dorsi was performed in all 
calves (12 steers and 12 heifers) at the level of the pelvis between the iliac, coxal and ischial 
tuberosity to obtain a minimum sample of tissue for subsequent gene expression analysis. 
Muscle biopsies were placed into a 2 mL Cryovial tube containing RNAlater (Ambion Inc., 
Austin, TX, USA) and stored in a −20°C freezer for subsequent laboratory analysis. In 
addition, blood samples (10 mL) were collected from all steers via jugular venipuncture into 
Tempus Blood RNA Tubes (Life Technologies, Carlsbad, CA, USA) at 0, 3, 6, and 15 dpw 
for subsequent gene expression analysis. Blood samples were immediately put on ice and 
stored at −80°C until later laboratory analysis. Although 30 cows were initially used in the 
trial, subsequent analyses were performed on a subset of samples because of costs. Thus, a 
random sample of 24 calves (12 steers and 12 heifers) and 12 steers (one from each pen) 
were used for muscle and blood analyses, respectively. Since, four time-points were sampled 
for blood, we opted to analyze just one sex to avoid increasing complexity of the statistical 
models and excessive costs. 
 
RNA Extraction, Sequencing, and Bioinformatics 
Total RNA from muscle and blood samples were extracted using RNeasy Fibrous 
Tissue Mini Kit (Qiagen Inc., Germantown, MD, USA) and TempusTM RNA isolation kit 
(Applied Biosystems, Foster City, CA, USA), respectively. The RNA quantity and quality 
were determined by Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, 
USA). One muscle and one blood samples were excluded from subsequent analysis due to 
low RNA integrity number (RIN) score (RIN < 8). All remaining samples were sent out to 
the Genomic Sciences Laboratory (North Carolina State University, Raleigh, NC, USA) for 
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library construction and RNA-sequencing. Sequencing was performed on an Illumina 
NextSeq 500 instrument (Illumina, Inc., San Diego, USA), generating 75 bp paired-reads and 
150 bp single-end reads for muscle and blood, respectively. A total of 2 and 3 flow cells were 
used, respectively, for muscle and blood samples, with approximately equal representation of 
treatments between flow cells. 
Quality of raw reads were evaluated with FastQC [21]. Sequence reads for each 
sample were mapped to the Bos taurus UMD3.1 reference genome using Bowtie2 [22]. The 
number of counts for each sample was obtained with the Subread package from SourceForge 
[23]. A total of 2,076,680,240 paired-ends and 1,353,110,288 single-ends reads were 
generated for muscle and blood samples, respectively, with an average of 90,290,445 and 
28,789,580 reads/sample, respectively. Reads were mapped to a total of 77.43% (19,045) and 
78.59% (19,331) genes for muscle and blood, respectively, from a total of 24,596 annotated 
genes in the UMD3.1 Bos taurus reference genome. Genes with less than four times the 
number of counts as samples were eliminated to avoid low counts across multiple samples, 
resulting in a final set of 15,255 and 13,512 genes for muscle and blood, respectively. For 
normalization of the data, we used Trimmed Mean of M-values (TMM) to calculate the 
normalization factors (TCC package [24]). The normalized library size was obtained by 
dividing the total library size by the normalized factors. 
 
Statistical Analyses  
Gene expression data was analyzed with a negative binomial model and a log link 
function [25]. Different models were tested for each tissue. For muscle, a negative binomial 
function was used in the following model: 
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𝑌&'"ghv = 𝜇 +	𝐷& +	𝑆' +	 𝐷 ∗ 𝑆 &' + 𝐵" + 𝑃g 	+	bC 𝑅&'"ghv − 𝑅+ b- 𝐷𝑂𝑇&'"ghv − 𝐷𝑂𝑇 +	𝑆𝑆v + 	𝑙𝑜𝑔 𝐿&'"ghv  
 
where, Yijklmn is the raw number of counts; µ is the intercept, Di is the fixed-effect of the ith 
Diet; Sj is the fixed effect of the jth Sex; Bk is the fixed effect of the kth Batch (sequencing 
lane); Pl is the fixed effect of the lth Pen; β1 is the partial regression coefficient for the 
covariate RIN scores (R); β2 is the partial regression coefficient for Days on Dietary 
Treatment (DOT); SSn is the fixed effect of the nth Service Sire; and Lijklmn is the TMM-
normalized library size, used as an offset. In addition to this model, 3 other reduced models 
were tested, in which the effects of pen and/or the interaction were removed. All models 
were used for each of the 15,255 genes, and the final model for each gene was chosen based 
on Akaike information criterion (AIC). 
For the gene expression analysis of blood samples, a negative binomial function was 
used in the following model: 
 𝑌&'"ghv = 𝜇 + 𝐷& +	𝑇' +	(𝐷 ∗ 𝑇)&' +	𝐵" + bC 𝑅&'"ghv − 𝑅 + b- 𝐷𝑂𝑇&'"ghv − 𝐷𝑂𝑇+	𝑆𝑆v + 	𝑙𝑜𝑔 𝐿&'"ghv  
where, Y, µ is the intercept, and D, B, R, L, DOT, and SS are as previously defined. Tj is the 
fixed effect of the jth Time. A reduced model without interaction was tested, and analyses 
were performed using three covariance structures for the residuals: first-order autoregressive, 
compound symmetry, and independent residuals. Therefore, 6 models were tested for each of 
the 13,512 genes, and the final model for each gene was selected based on AIC. Satterthwaite 
approximation to account for sample variances was used to determine the denominator 
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degrees of freedom. The dispersion parameter of the model was calculated for each gene 
squeezing towards a global dispersion with an approach assuming mean and variance related 
by 𝜎- = 	µ + 𝑎µ-	[26], where 𝑎 is a proportionality constant, using the package edgeR in R 
software [27].  
Additional contrasts were constructed in order to answer biologically relevant 
questions in the analysis of blood samples. Contrasts were developed for both the interaction 
effect (diet-by-time) and the main effect of time. For the main effect of time, two contrasts 
with 1-degree-of-freedom (df) were constructed: (1) to test the effect of vaccination (i.e. 
average of days 0, 3, and 6, versus day 15), and (2) to evaluate the acute response to weaning 
(i.e. day 0 versus average of days 3 and 6). For the interaction effect, these same contrasts 
were constructed, but accommodating their interaction with diet. 
False-discovery rate (FDR [28]) was used to adjust the P-values (q-values) of model 
terms due to multiple testing. Significant DEG were identified at q-value ≤ 0.05 for all 
analyses. All data were analyzed using the GLIMMIX procedure of SAS 9.4 (Statistical 
Analysis System Institute, Inc., Cary, NC, USA). 
 
Functional Annotation Analysis 
The enrichment of Gene Ontology (GO) terms associated with DEG was analyzed 
using PANTHER Enrichment Analysis [29]. Different DEG lists were created based on the 
significance (q-value < 0.05) of effects in the model. For the muscle data, analyses were 
performed separately for DEG based on diet and sex. For blood, we performed 3 analyses, 
one based on the effect of diet, and two based on the previously described contrasts (effect of 
vaccination and weaning). The Bos taurus genome was used as the background list. 
Biological Processes was considered significant at P-value < 0.05.  
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Gene-Network Analysis 
Two gene networks were constructed for the effect of diet: one using the most 
significant top 20 DEG in the muscle, and another using the top 10 DEG for the effect of diet 
in muscle associated with the top 10 DEG in blood. Partial correlation networks were 
constructed using gene counts pre-adjusted for all effects in the model, with the exception of 
diet (the effect of interest). In other words, the data used in this analysis, for each individual, 
represented the sum of the estimated diet effect and its residual. For the network including 
DEG from muscle and blood tissues, only data from steers were used as only male offspring 
had data using both tissues. Connections between genes (i.e. edges) were included when a 
pair of genes showed a partial correlation greater than |0.5|. The correlation matrix and gene-
networks were constructed using the ppcor [30] and qgraph [31] packages in R software 
[27].  
 
Results 
DEG Identification 
The number of DEG identified in this study is shown in Figure 2.1. A total of 160, 
164, and 346 DEG (q-value < 0.05) were identified in the muscle for the effects of diet, sex, 
and diet-by-sex interaction, respectively (Figure 2.1A). For blood, 452, 1392, and 155 DEG 
(q-value < 0.05) were identified for the effects of diet, time, and diet-by-time interaction, 
respectively (Figure 2.1B). For the contrasts in blood tissue, there were 101 and 47 DEG (q-
value < 0.05) for Weaning and Vaccination, respectively, based on the diet-by-time 
interaction effect (q-value < 0.05). For the main effect of Time (q-value < 0.05), there were 
893 and 473 DEG (P-value < 0.05) for Weaning and Vaccination contrasts, respectively. 
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Figure 2.1 Venn Diagram. Number of differentially expressed genes (DEG; q-value < 0.05) 
for the effects of diet, sex, and diet-by-sex for muscle (A), and diet, sex and diet-by-time for 
blood (B). 
 
Volcano plots for the effect of diet are shown in Figure 2.2. For the effect of sex in 
the muscle, there was a greater number of up-regulated genes for females (117) compared 
with males (47) (Figure 2.2A). There was a greater number of down-regulated (131) genes in 
the REST compared to up-regulated (29) in the muscle tissue (Figure 2.2B). In contrast, there 
was a much greater number of up-regulated genes in the REST (410) compared to down-
regulated (42) in the blood (Figure 2.2C).  
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Figure 2.2 Volcano plots for the effect of sex (A) and diet (B) in the muscle tissue, and for the 
effect of diet blood (C) tissue. The Y-axis shows the –log10 q-values for the effect of diet, 
whereas the X-axis represents the log2 fold change, with negative and positive values 
representing the down- and up-regulation of DEG in the restriction-enetgy group (REST), 
respectively. Genes with significant (q-value < 0.05) effect of diet are highlighted in red. 
 
A
B
C
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Enrichment Analysis in the Muscle  
The results of the enrichment analysis for diet and sex are presented in Table 2.1. 
Results based on diet (P < 0.05) showed genes involved in muscle metabolism, i.e. positive 
regulation of actin cytoskeleton reorganization (GO:2000251), positive regulation of 
collagen biosynthetic process (GO:0032967), adipose tissue development (GO:0060612) and 
positive regulation of collagen metabolic process (GO:0010714); and nervous system 
metabolism, i.e regulation of neuron differentiation (GO:0045664), regulation of 
neurogenesis (GO:0050767), regulation of nervous system development (GO:0051960), and 
negative regulation of neuron projection development (GO:0010977). Enrichment analyses 
for the effect of sex showed that DEG were enriched for categories related to nucleic acid 
metabolic process, such as histone H3-K27 demethylation (GO:0071557), DNA-dependent 
DNA replication (GO:0006261), DNA replication initiation (GO:0006270), and DNA repair 
(GO:0006281); and metabolism of carbohydrate and muscle, such as positive regulation of 
glycoprotein biosynthetic process (GO:0010560), regulation of skeletal muscle contraction 
(GO:0014819), and regulation of glycogen metabolic process (GO:0070873). Additional 
results (P < 0.05) including biological function GO terms for the effects of diet and sex can 
be seen in APPENDIX. 
Table 2.1 Enrichment analysis showing top 20 overrepresented1 Biological Processes for 
Differentially Expressed Genes2 for the effects of diet and sex in the muscle tissue 
Biological Process # genes FE P-value 
Diet    
 Positive regulation of transport (GO:0051050) 14 2.92 3.81E-04 
 Regulation of neuron projection development (GO:0010975) 8 4.27 7.09E-04 
 Negative regulation of myeloid cell differentiation (GO:0045638) 4 9.56 1.02E-03 
 Regulation of neuron differentiation (GO:0045664) 9 3.32 1.86E-03 
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 Table 2.1 continued     
 Biological Process # genes FE P-value 
 Positive regulation of blood vessel endothelial cell migration (GO:0043536) 3 13.21 1.90E-03 
 Regulation of transport (GO:0051049) 20 2.08 2.13E-03 
 Regulation of cell morphogenesis involved in differentiation (GO:0010769) 6 4.55 2.44E-03 
 Regulation of cell morphogenesis (GO:0022604) 8 3.33 3.28E-03 
 Regulation of intracellular transport (GO:0032386) 7 3.55 4.16E-03 
 Regulation of protein targeting (GO:1903533) 4 6.33 4.26E-03 
 Membrane depolarization (GO:0051899) 3 9.4 4.70E-03 
 Positive regulation of actin cytoskeleton reorganization (GO:2000251) 2 21.68 4.88E-03 
 Peptidyl-proline hydroxylation (GO:0019511) 2 21.68 4.88E-03 
 Regulation of mitochondrion organization (GO:0010821) 5 4.49 5.87E-03 
 Negative regulation of hemopoiesis (GO:1903707) 4 5.75 5.90E-03 
 Cell surface receptor signaling pathway (GO:0007166) 20 1.87 6.52E-03 
 Regulation of nervous system development (GO:0051960) 10 2.55 6.61E-03 
 Regulation of neurogenesis (GO:0050767) 9 2.68 7.28E-03 
 Regulation of localization (GO:0032879) 25 1.74 7.58E-03 
 Regulation of plasma membrane bounded cell projection organization (GO:0120035) 8 2.86 7.79E-03 
Sex    
 Kinetochore assembly (GO:0051382) 3 52.18 5.64E-05 
 Kinetochore organization (GO:0051383) 3 34.79 1.52E-04 
 Positive regulation of glycoprotein biosynthetic process (GO:0010560) 3 34.79 1.52E-04 
 Positive regulation of glycoprotein metabolic process (GO:1903020) 3 29.82 2.25E-04 
 Regulation of glucose metabolic process (GO:0010906) 5 9.53 2.41E-04 
 Chromosome organization (GO:0051276) 17 2.59 3.56E-04 
 Centromere complex assembly (GO:0034508) 3 21.97 4.97E-04 
 Establishment of melanosome localization (GO:0032401) 3 20.87 5.68E-04 
 Regulation of cellular carbohydrate metabolic process (GO:0010675) 5 7.65 
6.29E-04 
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 Table 2.1 continued     
 Biological Process # genes FE P-value 
 Establishment of pigment granule localization (GO:0051905) 3 19.88 6.46E-04 
 Melanosome localization (GO:0032400) 3 19.88 6.46E-04 
 Pigment granule localization (GO:0051875) 3 18.98 7.30E-04 
 Histone H3-K27 demethylation (GO:0071557) 2 55.66 1.04E-03 
 ATP hydrolysis coupled transmembrane transport (GO:0090662) 3 16.06 1.14E-03 
 ATP hydrolysis coupled proton transport (GO:0015991) 3 16.06 1.14E-03 
 Regulation of carbohydrate metabolic process (GO:0006109) 5 6.5 1.26E-03 
 Cellular macromolecular complex assembly (GO:0034622) 14 2.57 1.32E-03 
 Energy coupled proton transmembrane transport, against electrochemical gradient (GO:0015988) 3 14.91 1.38E-03 
 Positive regulation of sodium ion transmembrane transporter activity (GO:2000651) 2 39.76 1.76E-03 
 Regulation of skeletal muscle contraction (GO:0014819) 2 34.79 2.19E-03 
1P-value < 0.05; 
2q-value < 0.05; 
FE = fold enrichment 
 
Major DEG in the Skeletal Muscle 
The most top 10 significant up- and down-regulated DEG in the REST are 
summarized in Table 2.2. Of these, the most significant up- and down-regulated gene in the 
REST were SLCO3A1 and ETNPPL, with log2FC of -0.37 ± 0.06 (q-value = 4.58E-07) and 
0.41 ± 0.08 (q-value = 1.56E-04), respectively. The largest |log2FC| was observed for 
GTF2A1L, with -6.01 ± 1.67 (q-value = 3.60E-02).  
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Table 2.2 Top 10 up- and down-regulated most differentially expressed genes1,2 in the muscle 
tissue for the energy-restricted (REST) group 
Gene 
symbol Gene name Biological function Log2 FC ± SE q-value 
SLCO3A1 
Solute carrier 
organic anion 
transporter 
family member 
3A1 
Thyroid hormone 
membrane transporter 
involved in satellite cell 
differentiation [32] 
-0.37 ± 0.06 4.58E-07 
LAT 
Inker for 
activation of T 
cells 
T cell activation [33] -0.66 ± 0.11 1.91E-05 
MLX 
MAX 
dimerization 
protein 
Control cell cycle [34] -0.28 ± 0.05 2.44E-05 
TSPAN7 Tetraspanin 7 
Maturation of 
glutamatergic synapses 
[35] 
-0.31 ± 0.06 1.31E-04 
ATP6V0D1 
ATPase H+ 
transporting V0 
subunit d1 
Involved in oxidative 
phosphorylation [36]  -0.17 ± 0.03 1.67E-04 
SLC2A1 
Solute carrier 
family 2 
member 1 
Glucose transporter [37] -0.69 ± 0.13 1.67E-04 
RASL10B RAS like family 10 member B 
Potential tumor 
suppression [38] -0.97 ± 0.19 6.60E-04 
GPC4 Glypican 4 Involved in cell proliferation [39] -0.31 ± 0.06 1.41E-03 
RTF2 
Replication 
termination 
factor 2 
Riboflavin transporters 
[40] -0.17 ± 0.04 1.62E-03 
RASD2 RASD family member 2 
Involved in cellular 
movement and cell 
cycle [41] 
-0.39 ± 0.08 2.25E-03 
ETNPPL 
Ethanolamine-
phosphate 
phospholyase 
Associated to fatty acid 
and lipid metabolic 
process [42] 
0.41 ± 0.08 1.56E-04 
TRAPPC6B 
Trafficking 
protein particle 
complex 6B 
Vesicle transport [43] 0.14 ± 0.03 5.42E-04 
SMIM11A 
Small integral 
membrane 
protein 11A 
 0.33 ± 0.07 8.36E-04 
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Table 2.2 continued  
Gene 
symbol Gene name Biological function Log2 FC ± SE q-value 
TMCC2 
Transmembrane 
and coiled-coil 
domain family 2 
Play a role in 
neurodegeneration [44] 0.27 ± 0.06 2.91E-03 
SYT3 Synaptotagmin 3 
Involved in glucose 
metabolism [45] 0.92 ± 0.20 3.75E-03 
SPATA Spermatogenesis associated 1 
Involved in male 
fertility [46] 1.19 ± 0.27 3.91E-03 
AQP4 Aquaporin 4 Water channels [47] 0.70 ± 0.16 3.97E-03 
ETFRF1 
Electron transfer 
flavoprotein 
regulatory factor 
1 
Involved in fatty acid 
oxidation [48] 0.31 ± 0.07 3.97E-03 
CHN1 Chimerin 1 GTPase-activating protein [49] 0.57 ± 0.13 5.59E-03 
FZD5 Frizzled class receptor 5 
Wnt/Wingless (Wg) 
signals [50] 0.88 ± 0.21 8.00E-03 
1q-value < 0.05; 
2Up- and down-regulated in the groups are represented by positive and negative log2FC 
estimates, respectively; 
Biological Function based on cited reference; 
SE = Standard Error  
 
The most significant top 10 DEG for the effect of sex are summarized in Table 2.3. 
The most significant gene up-regulated in males was RIMS1 with log2FC of -2.83 ± 0.24 (q-
value = < 1.00E-13), and in females was SYAP1 with 0.35 ± 0.04 (q-value = < 1.00E-13). 
The largest |log2FC| was observed for LOC107131189 with -6.64 ± 0.24 (q-value =< 1.00E-
13).  
Table 2.3 Top 10 most differentially expressed genes1,2 in the muscle tissue for the effect of 
sex. 
Gene symbol Gene name Biological function Log2 FC ± SE q-value 
RIMS1 
Regulating 
synaptic 
membrane 
exocytosis 1 
Maintenance 
of normal 
synaptic function 
[51] 
-2.83 ± 0.24 < 1.00E-13 
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Table 2.3 continued    
Gene symbol Gene name Biological function Log2 FC ± SE q-value 
LOC107131189 
Eukaryotic 
translation 
initiation factor 2 
subunit 3, Y-
linked-like 
 -6.64 ± 0.13 < 1.00E-13 
LOC107131205 
Lysine-specific 
demethylase 6A-
like 
Antioxidant [52] -3.86 ± 0.35 < 1.00E-13 
CD3G CD3g molecule T-cell receptor [53] -1.85 ± 0.17 8.08E-05 
ADAM1B 
A disintegrin and 
metallopeptidase 
domain 1b 
Involved in male 
fertilization [54] -0.90 ± 0.18 1.15E-04 
ANOS1 Anosmin 1 Cell adhesion [55] -0.92 ± 0.26 2.20E-04 
ACTL8 Actin like 8  -1.33 ± 0.04 2.45E-04 
ARID1B 
AT-rich 
interaction 
domain 1B 
Regulation of cell 
cycle [56] -0.20 ± 0.25 2.77E-04 
GCGR Glucagon receptor Glucagon receptor [57] -1.20 ± 0.09 6.00E-04 
ZBED1 Zinc finger BED-type containing 1 
Associated with 
cell proliferation 
[58] 
-0.42 ± 0.24 1.22E-03 
SYAP1 
Synapse 
associated protein 
1 
 0.35 ± 0.04 < 1.00E-13 
KDM6A Lysine demethylase 6A Demethylase [59] 0.74 ± 0.07 < 1.00E-13 
EIF2S3 
Eukaryotic 
translation 
initiation factor 2 
subunit gamma 
Play a role in 
pituitary 
development and 
insulin secretion 
[60] 
0.57 ± 0.05 < 1.00E-13 
TXLNG Taxilin gamma  0.95 ± 0.13 8.48E-10 
ZRSR2 
Zinc finger 
CCCH-type, RNA 
binding motif and 
serine/arginine 
rich 2 
 0.69 ± 0.10 4.27E-08 
SRD5A3 Steroid 5 alpha-reductase 3 
Produces steroid 
hormones [61] 0.46 ± 0.07 6.49E-08 
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Table 2.3 continued   
Gene symbol Gene name Biological function Log2 FC ± SE q-value 
TMCC2 
Transmembrane 
and coiled-coil 
domain family 2 
 0.36 ± 0.06 1.30E-05 
FAAP24 
Fanconi anemia 
core complex 
associated protein  
DNA damage 
response [62] 1.10 ± 0.20 1.67E-05 
USP9X 
Ubiquitin specific 
peptidase 9, X-
linked 
TGF-β signaling 
[63] 0.32 ± 0.06 1.15E-04 
ICMT 
Isoprenylcysteine 
carboxyl 
methyltransferase 
Methyltransferase 
[64] 0.31 ± 0.06 1.26E-04 
1q-value < 0.05; 
2Negative and positive log2FC estimates represents up-regulated in males and females, 
respectively; 
Biological Function based on cited reference; 
SE = Standard Error 
 
Enrichment Analysis in the Blood 
The enrichment analyses for the different sets of DEG in the blood are presented in 
Table 2.4. Results based on diet showed general metabolic functions (P < 0.01), such as 
translation (GO:0006412), rRNA metabolic process (GO:0016072), and biosynthetic process 
(GO:0009058) in addition to carbohydrate metabolism such as regulation of carbohydrate 
metabolic process (GO:0006109) and glycogen metabolic process (GO:0005977). In 
contrast, for results based on biologically relevant contrasts, there was an overrepresentation 
of biological processes related to immune response for the effect of vaccination, such as 
immune system process (GO:0002376), regulation of response to stimulus (GO:0048583), 
and positive regulation of response to stimulus (GO:0048584), in addition to other general 
biological processes, such as localization (GO:0051179), and transport (GO:0006810). For 
the effect of weaning, we found GO terms associated with response to stress and the immune 
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system, i.e. cellular response to DNA damage stimulus (GO:0006974), response to stress 
(GO:0006950), regulation of lymphocyte activation (GO:0051249) and response to 
interleukin-4 (GO:0070670). Additional enrichment analysis results (P < 0.05) including GO 
terms for the effects of time (weaning and vaccination) can be seen in the APPENDIX. 
Table 2.4 Enrichment analysis showing the top 20 overrepresented1 Biological Process for 
Differentially Expressed Genes2 for diet and biologically relevant contrasts in the blood 
tissue (effect of weaning and vaccination) 
 Biological Process # genes FE P-value 
Diet    
 Translation (GO:0006412) 22 4.3 3.42E-08 
 Cellular component biogenesis (GO:0044085) 36 2.08 6.01E-05 
 rRNA metabolic process (GO:0016072) 10 3.77 5.20E-04 
 Cellular component organization or biogenesis (GO:0071840) 65 1.48 1.68E-03 
 Biosynthetic process (GO:0009058) 55 1.49 4.07E-03 
 Organelle organization (GO:0006996) 39 1.51 1.36E-02 
 Regulation of carbohydrate metabolic process (GO:0006109) 3 6.54 1.37E-02 
 Transcription initiation from RNA polymerase II promoter (GO:0006367) 4 3.81 2.47E-02 
 Protein localization (GO:0008104) 18 1.72 2.71E-02 
 Protein targeting (GO:0006605) 8 2.3 2.73E-02 
 Primary metabolic process (GO:0044238) 119 1.19 3.26E-02 
 Cellular component organization (GO:0016043) 54 1.32 3.77E-02 
 Glycogen metabolic process (GO:0005977) 3 4.03 4.38E-02 
Weaning    
 Translation (GO:0006412) 101 5.84 6.58E-42 
 Peptide biosynthetic process (GO:0043043) 101 5.64 8.81E-41 
 Amide biosynthetic process (GO:0043604) 103 5.09 3.67E-38 
 Peptide metabolic process (GO:0006518) 103 4.8 3.40E-36 
 Cellular amide metabolic process (GO:0043603) 106 4.08 7.70E-32 
 Cellular macromolecule biosynthetic process (GO:0034645) 181 2.21 4.73E-23 
 Macromolecule biosynthetic process (GO:0009059) 181 2.17 1.99E-22 
 Organonitrogen compound biosynthetic process (GO:1901566) 125 2.68 4.22E-22 
 Cellular nitrogen compound biosynthetic process (GO:0044271) 165 2.11 4.11E-19 
 Cellular macromolecule metabolic process (GO:0044260) 293 1.62 1.85E-18 
 Cellular protein metabolic process (GO:0044267) 213 1.84 3.63E-18 
 Organic substance biosynthetic process (GO:1901576) 203 1.8 2.37E-16 
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 Table 2.4 continued    
 Biological Process # genes FE P-value 
 Cellular nitrogen compound metabolic process (GO:0034641) 232 1.7 3.41E-16 
 Cellular biosynthetic process (GO:0044249) 198 1.8 9.94E-16 
 Biosynthetic process (GO:0009058) 204 1.76 1.74E-15 
 Protein metabolic process (GO:0019538) 232 1.64 1.84E-14 
 Gene expression (GO:0010467) 168 1.85 3.42E-14 
 Organelle organization (GO:0006996) 178 1.74 6.55E-13 
 Macromolecule metabolic process (GO:0043170) 320 1.42 2.33E-12 
 Cellular component organization or biogenesis (GO:0071840) 252 1.52 2.74E-12 
 Ribosome biogenesis (GO:0042254) 37 3.65 1.55E-10 
Vaccination    
 Localization (GO:0051179) 141 1.61 3.46E-09 
 Establishment of localization (GO:0051234) 110 1.6 6.83E-07 
 Immune system process (GO:0002376) 58 1.93 2.65E-06 
 Transport (GO:0006810) 104 1.57 3.50E-06 
 Positive regulation of GTPase activity (GO:0043547) 22 3.18 4.20E-06 
 Cellular response to chemical stimulus (GO:0070887) 67 1.75 1.25E-05 
 Regulation of GTPase activity (GO:0043087) 23 2.87 1.27E-05 
 Regulation of response to stimulus (GO:0048583) 97 1.54 2.14E-05 
 Positive regulation of response to stimulus (GO:0048584) 56 1.78 3.82E-05 
 Positive regulation of hydrolase activity (GO:0051345) 28 2.4 3.93E-05 
 Cellular response to organic substance (GO:0071310) 55 1.77 5.19E-05 
 Cell differentiation (GO:0030154) 84 1.53 8.59E-05 
 Regulation of response to external stimulus (GO:0032101) 26 2.35 9.76E-05 
 Transition metal ion transport (GO:0000041) 9 5.07 1.32E-04 
 Cellular homeostasis (GO:0019725) 28 2.24 1.36E-04 
 Developmental process (GO:0032502) 118 1.39 1.65E-04 
 Regulation of hydrolase activity (GO:0051336) 40 1.92 1.71E-04 
 Myeloid leukocyte activation (GO:0002274) 8 5.47 1.93E-04 
 Positive regulation of response to external stimulus (GO:0032103) 14 3.22 2.06E-04 
 Regulation of signaling (GO:0023051) 83 1.5 2.22E-04 
 Regulation of signal transduction (GO:0009966) 77 1.53 2.22E-04 
1P-value < 0.05; 
2q-value < 0.05; 
FE = fold enrichment 
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Major DEG in Blood Tissue 
The effect of the interaction diet-by-time was analyzed based on biologically relevant 
contrasts. The top 10 most significant DEG for the effect of interaction diet-by-weaning and 
diet-by-vaccination are summarized in Table 2.5. Of these, the most significant gene for the 
effect of the interaction diet-by-weaning was USF3 (q-value = 1.13E-04) and for the effect of 
diet-by-vaccination was LOC104968634 (q-value = 6.62E-04). In addition, we found genes 
related to immune system function and response to stress, such as KLRK1 [65] and INO80D 
[66], down and up-regulated, respectively, in the REST after weaning. When we looked at 
the effect of the interaction diet-by-vaccination, we found genes involved in immune 
response being down-regulated in the REST after vaccination, including OASL [67], KLRF1 
[65], and LOC104968634 [68].  
Table 2.5 Top 10 Differentially Expressed Genes1 in the blood for biologically relevant 
contrasts 
 Gene symbol Gene name Biological function q-value 
DEG for effect of diet-by-weaning interaction 
 USF3 Upstream trasnscription factor family member 3 USF3 1.13E-04 
 STARD6 
StAR related lipid 
transfer domain 
containing 6 
Structure and lipid transport 
mechanism [69] 3.10E-04 
 PHC3 Polyhomeotic homolog 3  3.17E-04 
 BRMS1L Breast cancer metastasis-suppressor 1 like Metastasis suppression [70] 4.87E-04 
 MPV17L 
MPV17L mitochondrial 
inner membrane protein 
like 
Up- or down-regulation of 
the genes of antioxidant 
enzymes [71] 
4.92E-04 
 NBEAL1 Neurobeachin like 1 
Vesicle trafficking, 
membrane dynamics and 
receptor signaling [72] 
7.31E-04 
 C5H12orf4 
Chromosome 5 open 
reading frame, human 
C12orf4 
 7.59E-04 
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 Table 2.5 continued   
 Gene symbol Gene name Biological function q-value 
 INO80D INO80 complex subunit D 
DNA damage responses 
[73] 8.00E-04 
 TIGD3 Tigger transposable element derived 3  8.94E-04 
 KLRK1 Killer cell lectin like receptor F1 
Stimulates natural killer 
(NK) cells cytoxicity and 
cytokine release [65] 
9.05E-04 
DEG for effect of diet-by-vaccination interaction 
 LOC104968634 Antimicrobial peptide NK-lysin-like Antimicrobial activity [68] 6.62E-04 
 GPR161 G protein-coupled receptor 161 
Involved in neural tube 
development [74] 2.13E-03 
 KLRF1 Killer cell lectin like receptor F1 
Stimulates NK cells 
cytoxicity and cytokine 
release [65] 
2.20E-03 
 PMCH Pro-melanin concentrating hormone Feed intake control [75] 2.81E-03 
 PIK3C2G 
Phosphatidylinositol-4-
phosphate 3-kinase 
catalytic subunit type 2 
gamma 
Control cell proliferation 
[76] 3.15E-03 
 KRT24 Keratin 24  3.64E-03 
 PRRT3 Proline rich transmembrane protein 3 Protein binding [77] 3.74E-03 
 QRICH2 Glutamine rich 2 Cupper regulation [78] 4.18E-03 
 HIST2H2AB Histone cluster 2 H2A family member B 
Play a central role in 
transcription regulation, 
DNA repair and DNA 
replication [79] 
4.22E-03 
 OASL 2'-5'-oligoadenylate synthetase like 
Response to viral infections 
[67] 4.73E-03 
1P-value < 0.05 for significant (q-value < 0.05) effects of diet-by-time interaction or time; 
Biological Function based on cited reference; 
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Partial Correlation Network in the Muscle and Blood 
The partial correlation network using the 20 most DEG (q-value < 0.05) is depicted in 
Figure 2.3. On average, each gene was connected to 9.8 genes, with ATP6V0D1 and TMCC2 
showing the greatest number of connections (15 genes) between them, and MATK the least (2 
genes).  
 
Figure 2.3 Partial correlation network for top 20 differentially expressed genes (q-value < 
0.05) for the effect of diet in muscle tissue. Red and blue nodes represent down- and up-
regulated genes in the restricted group (REST). 
 
The partial correlation network linking the 10 most DEG in muscle with the 10 most 
DEG in blood is shown in Figure 2.4. On average, each gene was connected to 3.4 genes. 
The gene LOC512150 (MYADM) showed the highest connectivity (8 genes) between them. 
Just one gene (ETNPPL) was not connected using correlation > |0.50|. LOC512150 
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(MYADM) was up-regulated in REST in the blood and ETNPPL was down-regulated in the 
REST in the muscle. In addition, we found 7 DEG simultaneously in muscle and blood: 
SPAG17, VAT1, CABLES1, SLC20A2, ILF3, QDPR, and LOC107131247. Among them, 
VAT1, CABLES1, SLC20A2, ILF3, and QDPR were down-regulated in muscle and up-
regulated in blood, and SPAG17 and LOC107131247 were up-regulated in both. 
 
Figure 2.4 Partial correlation networks for the top 20 differentially expressed genes (DEG; 
q-value < 0.05) for the effect of diet - 10 from muscle associated with 10 from blood tissue. 
Red and blue nodes represent differentially expressed genes in blood and muscle tissues, 
respectively.  
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Discussion 
Overall Discussion 
Alterations in the intra-uterine environment, such as those caused by maternal 
nutrition during pregnancy, can modify prenatal development, which can lead to positive or 
negative consequences in the adult life of the animal [2,80]. In addition to the pre-natal 
vulnerability, the pre-conditioning phase is also critical for offspring development since the 
animal is going through a stressful period and may have its performance compromised. 
Therefore, a well-developed immune system, associated with proper development of muscle 
tissue, would favor the productive performance of the animal. Our study focused on the 
effect of maternal energy restriction during late gestation on the transcriptomic profile in 
skeletal muscle and blood tissues in the offspring. 
In skeletal muscle tissue, 131 of the 160 DEG were down-regulated in the REST vs 
CTRL, suggesting that maternal energy restriction during late gestation may limit the 
expression of genes in the muscle of calves. On the other hand, there was a numerical 
increase in up-regulation of genes in the REST (410 out of 452) compared to the CTRL 
group, in the blood of the calves. Although we do not have the data to conclude on this, this 
clear gene-regulation bias towards one diet or the other could be due to maternal energy 
restriction causing epigenetic modifications in the fetal genome. 
 
Enrichment Analyses in the Muscle 
Enrichment analysis in the muscle showed an overrepresentation of genes associated 
with metabolism. Most of them are of general categories, such as regulation of transport 
(GO:0051049), regulation of localization (GO:0032879), and regulation of intracellular 
transport (GO:0032386), but we also found more relevant categories related to muscle 
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metabolism such as positive regulation of actin cytoskeleton reorganization (GO:2000251), 
positive regulation of collagen biosynthetic process (GO:0032967), and positive regulation 
of collagen metabolic process (GO:0010714). These functional terms support that maternal 
nutrition alters metabolic processes in fetal tissues as previously observed by Mortensen et 
al.[81]. Those authors found that the maternal pre-natal diet with low protein fed at 
isoenergetic intake in mice caused down-regulation of several pathways related to energetic 
metabolism processes including glycolysis, citrate cycle, and amino acid degradation, in 
skeletal muscle in newborns. 
DEG for the effect of sex were enriched for very general biological processes, most 
of which were associated with acid nucleic metabolism (e.g. histone H3-K27 demethylation 
(GO:0071557), DNA-dependent DNA replication (GO:0006261), DNA replication initiation 
(GO:0006270), and DNA repair (GO:0006281)) in addition to metabolism of carbohydrate 
and muscle (i.e. positive regulation of glycoprotein biosynthetic process (GO:0010560), 
regulation of skeletal muscle contraction (GO:0014819), and regulation of glycogen 
metabolic process (GO:0070873). The enrichment analysis results can be seen on Table 2. 
These functional terms are related to chromatin biology and epigenetics suggesting that these 
variations are responsible for the changes in gene expression observed in fetal tissues. Our 
study supports the hypothesis that males and females have different responses to fetal 
programming as has been shown previously. Differences in offspring outcomes according to 
their sex as an effect of fetal programming was reported in sheep [82,83] and cows [84,85]. 
 
Major DEG in Muscle Tissue 
From the top 10 down-regulated genes in the REST, we identified 5 genes associated 
with muscle metabolism and development as well as with energy metabolism: (1) SLCO3A1, 
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a membrane transporter of the thyroid hormone involved in satellite cell differentiation [32]; 
(2) ATP6V0D1, involved in oxidative phosphorylation [36]; (3) SLC2A1, a facilitator of 
glucose transport; (4) GPC4, involved in cell proliferation [39]; and (5) RASD2, expressed in 
satellite cells and involved in cellular movement and cell cycle. This connection of major 
genes with energy metabolism associated with the relevant functional terms in the 
enrichment analysis may indicate a shift in the way the tissues are generating energy in the 
REST compared with CRTL. We propose that energy is being produced primarily through 
the glycolytic pathway instead of the oxidative pathway, which is less efficient and occurs as 
a result of lack of sufficient energy. Concordantly, Daniel et al. [86] showed that maternal 
dietary restriction during mid-gestation increases the number of fast (type II) muscle fibers, 
which generate energy through glycolytic pathways, as a compensatory process due to 
limited energy availability for muscle development. Mitochondrial oxidative phosphorylation 
is the primary pathway to produce energy for metabolic activities, which generates more 
adenosine triphosphate (ATP) than glycolysis [87]; however, lack of energy can decrease the 
number of fast fibers [86], reducing the efficiency of energy production and, consequently, of 
metabolic activities. In accordance, Byrne et al. [88] suggested that caloric restriction may 
increase metabolism of amino acids to glucose via gluconeogenesis after finding increased 
gene expression levels associated with energy metabolism. Moreover, Peñagaricano et al. [9] 
showed that the maternal source of energy may affect gene expression in the muscle of 
sheep. These authors observed that dams fed a corn-based diet had greater expression of 
genes associated with embryonic and fetal development, skeletal muscle, tissue 
differentiation, muscle myosin complex, and sarcomere organization, than dams fed alfalfa 
haylage and distillers grains. These results indicate that the energy-restricted diet may be 
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impairing the development of muscle tissue as well as altering the energy metabolism in the 
offspring. In addition, Yang et al. [39] reported GP4 as less expressed due hypermethylation 
in Chinese pigs, which are known for having less lean muscle mass and low growth rate, 
suggesting that reduced gene expression may be occurring due epigenetic modifications. The 
downregulation of RASD2 in the REST may also indicates that maternal energy restriction 
alters the proliferation capacity of satellite cells, controlling the skeletal muscle hypertrophy. 
Raja et al. [41] have shown that energy restriction during gestation alters temporal expression 
of myogenic regulatory factors in satellite cells impairing the fusion of cells isolated from 3-
month old lambs. Therefore, alterations in maternal nutrition during pregnancy may lead to 
negative effects on postnatal myogenesis.  
In contrast, REST had increased expression of genes related to fatty acid and glucose 
metabolism, such as ETNPPL, associated with fatty acid and lipid metabolic process [42]; 
SYT3, involved in glucose metabolism [45]; and ETFRF1, involved in fatty acid oxidation 
[48]. The gene SYT3 has been shown to be up-regulated in a mutated mice lacking the gene 
RORα	and presenting lean phenotype, resistance to high fat diet, and insulin resistance [45]. 
This finding suggests that the REST presents an impaired glucose metabolism compared with 
the CTRL group, which may be influencing the increase in expression of genes associated 
fatty acid metabolism (ETNPPL and ETFRF1). In addition, the overexpression of FZD5 in 
the REST may indicate an disruption on the Wnt signaling pathway, which is related to 
diverse functions in developmental processes, including glucose metabolism [50]. These 
findings suggest that energy restriction during late pregnancy affects glucose metabolism and 
enhances fatty acid metabolism. 
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From the top 10 DEG for the effect of sex, in accordance with the enrichment 
analyses, we identified genes associated with chromatin biology and epigenetic 
modifications, such as KDM6A and ICMT up-regulated in females compared with males. 
From the top 10 DEG for the effect of sex, in accordance with the enrichment analyses, we 
identified genes associated with glucose metabolism, such as GCGR (up-regulated in males) 
and EIF2S3 (up-regulated in females) and chromatin biology and epigenetic modifications, 
such as KDM6A and ICMT up-regulation in females compared with males. In accordance, 
glucose metabolism had been thought to differ between male and female embryos [53]. In 
addition, Alvarez et al. [89] found higher transcriptional level in females compared with 
males. We propose that the X-linked genes inactivation in females may occur as a result of 
an imprinting mechanism leading to a total or partial maternal allele transcriptional 
repression [89], which can generate an up-regulation of genes in females compared with 
males (Figure 2.2). These results suggest that the different gene expression levels occur due 
to difference in sex chromosome dosage. 
   
Enrichment Analysis in the Blood Tissue 
For the analysis for DEG in the blood, we focused on the overall effect of diet and its 
effects as a function of vaccination and weaning. Biological processes related to major 
immune response activities and response to stress were identified for the effects of 
vaccination and weaning, respectively, such as cellular response to DNA damage stimulus 
(GO:0006974), response to stress (GO:0006950), regulation of lymphocyte activation 
(GO:0051249), response to interleukin-4 (GO:0070670) and immune system process 
(GO:0002376), suggesting that the maternal nutrition during pregnancy influenced the 
response of the offspring to the immune challenge after weaning and vaccination. It has been 
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shown that the immune challenge may elicit an acute phase response which decrease feed 
intake and increases protein demand to support the immune system [12,13] leading to 
compromised growth. The energy-restricted diet may be impairing the animal`s response in 
this phase, since the energy metabolism might be compromised and less efficient to 
synthesize protein for the immune system. 
 
Major DEG in Blood Tissue 
Among the top 10 major DEG for the effect of the diet-vs-weaning interaction, we found 
genes related to immune system and response to stress, such as KLRK1, which stimulates 
natural killer (NK) cells [65] and INO80D [73], involved in oxidation-reduction activity. 
KLRK1 was down-regulated and INO80D was up-regulated in the REST after weaning 
(Figure 2.5). In accordance with the results in the muscle tissue for the effect of energy-
restricted diet, we hypothesized that the REST triggered a more pronounced stress process 
than the CRTL during the acute response phase. 
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Figure 2.5 Top 10 differentially expressed genes (q-value < 0.05) showing interaction 
between the effects of diet and weaning in the blood tissue. Bars represent the log2 fold-
change for the effect (P-value < 0.05) of diet before (blue) and after (red) weaning, with 
error bars representing 95% confidence interval. Positive and negative values represent up- 
and down-regulation of genes in the restricted group (REST). The name and function of the 
genes are summarized in Table 5. 
 
When we looked at the effect of the diet-by-vaccination interaction, we found genes 
involved in immune response were down-regulated in the REST after vaccination (Figure 
2.6), such as OASL, which is involved in response to viral infections [67]; KLRF1, which is 
expressed on nearly all NK cells and stimulates their cytotoxicity and cytokine release [65]; 
and LOC104968634, an antimicrobial peptide stimulating NK cells cytoxicity. These 
findings suggest that the CRTL responded better to the immune challenge which may be due 
to better development of the immune system during pre-natal phase. Also, these data are in 
agreement with Moriel et al. [18], who used a portion of the data from this study, showed that 
70% of energy restriction during the last 40 days of gestation decreased post-weaning 
vaccination-induced humoral immunity, inflammatory, and physiological stress responses in 
calves. Our results support the hypothesis that maternal energy restriction during pregnancy 
can alter gene expression in the offspring associated with immune response which may 
reflect on the growth performance of the animal. 
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Figure 2.6 Top 10 differentially expressed genes (q-value < 0.05) showing interaction 
between the effects of diet and vaccination. Bars represent the log2 fold-change for the effect 
of diet for before (red) and after (blue) vaccination, and error bars represent 95% 
confidence interval. Positive and negative values represent up- and down-regulation of genes 
in the restricted group (REST). The name and function of the genes are summarized on Table 
5. 
 
Gene Networks 
From the gene-network for the top 20 major genes in muscle, the genes ATP6V0D1 
and TMCC2 showed highest connectivity and were negatively correlated to each other. 
TMCC2 and ATP6V0D1 were up- down-regulated in the REST, respectively, and ATP6V0D1 
plays an important role in energy metabolism as discussed previously. All genes showed 
connectivity with at least 2 other genes. 
The result from the partial correlation network linking DEG in muscle and blood 
(Figure 2.4) showed LOC512150 (MYADM) with highest connectivity (8), and ETNPPL with 
no connectivity. LOC512150 (MYADM) was up-regulated in the REST the blood and 
ETNPPL was down-regulated in the REST in muscle. LOC512150 (MYADM) encodes for 
cell-surface markers for immune cells, which supports the hypothesis that the CRTL group 
responded better to the immune challenge compared with the REST. 
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Among the DEG in both blood and muscle (SPAG17, VAT1, CABLES1, SLC20A2, 
ILF3, QDPR, and LOC107131247), most of them were down-regulated in muscle and up-
regulated in blood, except for SPAG17 and LOC107131247, which were down-regulated in 
both. Among the genes down-regulated in the muscle and up-regulated in blood, some of 
them are associated with the immune system and stress response, i.e. ILF3 [90], QDPR [91], 
CABLES1 [92], and LOC107131247 [93]. CABLES1 is a glucocorticoid-activated cell cycle 
regulator. Glucocorticoids are known to be involved in several growth-related functions, 
including enhanced response to stress and decreased protein synthesis in skeletal muscle. 
Therefore, the DEG expressed in both blood and muscle tissue may be playing different roles 
in each of the tissues.  
 
Conclusion 
This study indicates that reducing dietary energy in pregnant cows by 30% during the 
last 40 days of gestation impacts the transcriptomic profiling of skeletal muscle and blood 
tissues in the offspring. Maternal energy restriction reduced the expression of genes in the 
skeletal muscle tissue and increased the gene expression in blood. Specifically, we observed 
a reduced expression of genes associated with energy metabolism and muscle development in 
the skeletal muscle tissue. In blood tissue, there was a decrease in expression of genes 
associated with immune response and stress processes in the REST after weaning and 
vaccination. Also, we found that DEG in muscle and blood showed a connectivity between 
them, enhancing the importance of the immune system as a target tissue for the effect of 
maternal energy restriction during late pregnancy. These finding suggest that energy 
restriction during late pregnancy may trigger a more pronounced stress response in the 
offspring that may impair muscle growth and immune development. 
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CHAPTER 3. LIMITATIONS AND FUTURE DIRECTIONS 
In this thesis, we studied the effect of energy restriction during late gestation in the 
blood and muscle transcriptome of preconditioned beef calves. Maternal restriction during 
late gestation was shown to affect the regulation of genes associated with skeletal muscle 
metabolism and immune system of the offspring.  
During the development of this study, some assumptions were considered to 
overcome limitations. For example, the effect of weaning and vaccination were confounded 
with the effect of age. We believed this time effect would be minimum due to the small space 
of time between the collection of samples. To deal with this issue, it would be necessary to 
replicate the study adding one control group after weaning/vaccination to avoid the age 
effect. Also, the number of animals was small (6 animal in each group) especially if we think 
about the high biological variance between samples. Unfortunately, this is a recurrent issue in 
RNA-seq experiments since the cost of the technology is still a limitation. The number of 
sires used (two sires) was also a limitation of the study. The use of additional sires would 
allow us to make more general conclusions. Another limitation in this study was the time-
points used for sample collection. For example, collection of muscle and blood samples right 
after birth would allow us to have a better to understanding of the effects of the intrauterine 
environment on the post-natal transcriptome profile of the offspring. With an additional time-
point, we could compare changes in the expression levels of genes of interest.  
This study showed the importance of investigating the blood transcriptome profile as 
a function of maternal nutrition. Interesting, we identified several DEG associated with the 
immune response. However, there is little information in the literature regarding the 
development of the immune system in cattle during prenatal phase. Hence, we believe that in 
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future studies, the investigation of the blood transcriptome would be beneficial to enhance 
the current understanding how the immune system of the offspring can be affected by 
maternal nutrition. In addition, even with small number of samples, we were able to detect 
between-treatments gene expression variations. It would be also interesting to look the 
within-treatment variations due to individual differences. If we could perform this type of 
study at a much larger scale (e.g. 1,000 animals per treatment), we could estimate genetic 
parameters and perform genomic analyses for several traits as a function of maternal 
nutrition. The identification of genetic-by-treatment interaction would suggest different 
families would respond differently depending on the diet provided during gestation. This 
would have major implications to the livestock industry. Finally, since there is a strong 
hypothesis that the changes during fetal programming occur due to epigenetic modifications, 
it would be interesting to look for the DNA methylation and histone acetylation pattern in the 
offspring. The identification of imprinting genes between the DEG would also be an 
indicative of epigenetic modification, what would help to support this hypothesis. This study 
provides a list of candidate genes which have the level of expression affected as an effect of 
maternal energy restriction during late gestation. Based on the information obtained from the 
enrichment analysis associated with the most significant DEG, these genes may also be 
included (i.e. as genomic biomarkers) in future genomic selection methods using functional 
information. 
In conclusion, although several limitations must be recognized, this study was able to 
show the effect of maternal restriction during late gestation on the gene expression of the 
offspring. 
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APPENDIX. GENE SET ENRICHMENT ANALYSIS 
Table 0.1 Gene set enrichment analysis for muscle tissue  
 GO biological process complete #genes FE P-value 
Effect of diet  
 Positive regulation of transport (GO:0051050) 14 2.92 3.81E-04 
 Regulation of neuron projection development 
(GO:0010975) 
8 4.27 7.09E-04 
 Negative regulation of myeloid cell differentiation 
(GO:0045638) 
4 9.56 1.02E-03 
 Regulation of neuron differentiation (GO:0045664) 9 3.32 1.86E-03 
 Positive regulation of blood vessel endothelial cell 
migration (GO:0043536) 
3 13.21 1.90E-03 
 Regulation of transport (GO:0051049) 20 2.08 2.13E-03 
 Regulation of cell morphogenesis involved in 
differentiation (GO:0010769) 
6 4.55 2.44E-03 
 Regulation of cell morphogenesis (GO:0022604) 8 3.33 3.28E-03 
 Regulation of intracellular transport (GO:0032386) 7 3.55 4.16E-03 
 Regulation of protein targeting (GO:1903533) 4 6.33 4.26E-03 
 Membrane depolarization (GO:0051899) 3 9.4 4.70E-03 
 Positive regulation of actin cytoskeleton reorganization 
(GO:2000251) 
2 21.68 4.88E-03 
 Peptidyl-proline hydroxylation (GO:0019511) 2 21.68 4.88E-03 
 Regulation of mitochondrion organization (GO:0010821) 5 4.49 5.87E-03 
 Negative regulation of hemopoiesis (GO:1903707) 4 5.75 5.90E-03 
 Cell surface receptor signaling pathway (GO:0007166) 20 1.87 6.52E-03 
 Regulation of nervous system development (GO:0051960) 10 2.55 6.61E-03 
 Regulation of neurogenesis (GO:0050767) 9 2.68 7.28E-03 
 Regulation of localization (GO:0032879) 25 1.74 7.58E-03 
 Regulation of plasma membrane bounded cell projection 
organization (GO:0120035) 
8 2.86 7.79E-03 
 Positive regulation of collagen biosynthetic process 
(GO:0032967) 
2 16.58 7.80E-03 
 Positive regulation of collagen metabolic process 
(GO:0010714) 
2 16.58 7.80E-03 
 Regulation of cell projection organization (GO:0031344) 8 2.83 8.36E-03 
 Positive regulation of intracellular transport 
(GO:0032388) 
5 4.1 8.45E-03 
 Regulation of collagen synthetic process (GO:0032965) 2 15.66 8.62E-03 
 Positive regulation of mitochondrion organization 
(GO:0010822) 
4 5.08 8.95E-03 
 Regulation of blood vessel endothelial cell migration 
(GO:0043535) 
3 7.29 9.16E-03 
 Negative regulation of developmental process 
(GO:0051093) 
11 2.3 9.26E-03 
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 Table A.1 continued      
 GO biological process complete #genes FE P-value 
 Labyrinthine layer blood vessel development 
(GO:0060716) 
2 14.84 9.49E-03 
 Positive regulation of GTPase activity (GO:0043547) 7 2.98 1.02E-02 
 Plasma membrane organization (GO:0007009) 3 6.93 1.04E-02 
 Positive regulation of protein targeting to mitochondrion 
(GO:1903955) 
3 6.82 1.09E-02 
 Alpha-amino acid metabolic process (GO:1901605) 5 3.83 1.10E-02 
 Positive regulation of establishment of protein localization 
to mitochondrion (GO:1903749) 
3 6.71 1.14E-02 
 Positive regulation of catalytic activity (GO:0043085) 15 2.04 1.18E-02 
 Cellular response to tumor necrosis factor (GO:0071356) 4 4.66 1.19E-02 
 Regulation of multicellular organismal metabolic process 
(GO:0044246) 
2 12.81 1.23E-02 
 Regulation of protein targeting to mitochondrion 
(GO:1903214) 
3 6.41 1.28E-02 
 Positive regulation of cell communication (GO:0010647) 16 1.89 1.28E-02 
 Regulation of intracellular protein transport 
(GO:0033157) 
5 3.67 1.30E-02 
 Endomembrane system organization (GO:0010256) 6 3.17 1.30E-02 
 Protein hydroxylation (GO:0018126) 2 12.26 1.33E-02 
 Regulation of cell junction assembly (GO:1901888) 3 6.31 1.33E-02 
 Positive regulation of cellular component organization 
(GO:0051130) 
13 2.04 1.38E-02 
 Positive regulation of protein transport (GO:0051222) 7 2.8 1.39E-02 
 Regulation of vesicle-mediated transport (GO:0060627) 7 2.79 1.41E-02 
 Pigment cell differentiation (GO:0050931) 2 11.75 1.43E-02 
 Positive regulation of calcium-mediated signaling 
(GO:0050850) 
2 11.75 1.43E-02 
 Motor neuron axon guidance (GO:0008045) 2 11.75 1.43E-02 
 Positive regulation of endothelial cell migration 
(GO:0010595) 
3 6.13 1.44E-02 
 Regulation of establishment of protein localization to 
mitochondrion (GO:1903747) 
3 6.04 1.49E-02 
 Positive regulation of signal transduction (GO:0009967) 15 1.92 1.53E-02 
 Semaphorin-plexin signaling pathway (GO:0071526) 2 11.28 1.54E-02 
 T cell proliferation (GO:0042098) 2 11.28 1.54E-02 
 Cellular response to nitrogen compound (GO:1901699) 7 2.73 1.59E-02 
 Positive regulation of establishment of protein localization 
(GO:1904951) 
7 2.73 1.59E-02 
 Response to tumor necrosis factor (GO:0034612) 4 4.24 1.62E-02 
 Regulation of actin cytoskeleton reorganization 
(GO:2000249) 
2 10.84 1.65E-02 
 Cell-substrate adhesion (GO:0031589) 4 4.15 1.74E-02 
 Positive regulation of binding (GO:0051099) 4 4.12 1.78E-02 
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 Table A.1 continued      
 GO biological process complete #genes FE P-value 
 Regulation of secretion by cell (GO:1903530) 8 2.44 1.85E-02 
 Positive regulation of substrate adhesion-dependent cell 
spreading (GO:1900026) 
2 10.07 1.89E-02 
 Placenta blood vessel development (GO:0060674) 2 10.07 1.89E-02 
 Adipose tissue development (GO:0060612) 2 10.07 1.89E-02 
 Alpha-amino acid catabolic process (GO:1901606) 3 5.49 1.90E-02 
 Positive regulation of signaling (GO:0023056) 16 1.88 1.94E-02 
 Positive regulation of hydrolase activity (GO:0051345) 9 2.27 1.97E-02 
 Plasma membrane bounded cell projection assembly 
(GO:0120031) 
6 2.87 2.01E-02 
 Positive regulation of intracellular protein transport 
(GO:0090316) 
4 3.94 2.04E-02 
 Cell projection assembly (GO:0030031) 6 2.85 2.06E-02 
 Negative regulation of neuron projection development 
(GO:0010977) 
3 5.29 2.09E-02 
 Regulation of GTPase activity (GO:0043087) 7 2.57 2.11E-02 
 Positive regulation of ERK1 and ERK2 cascade 
(GO:0070374) 
4 3.89 2.13E-02 
 Regulation of myeloid cell differentiation (GO:0045637) 4 3.84 2.22E-02 
 Cellular response to oxygen levels (GO:0071453) 3 5.16 2.22E-02 
 Maturation of LSU-rRNA (GO:0000470) 2 9.09 2.26E-02 
 Negative regulation of immune system process 
(GO:0002683) 
6 2.78 2.28E-02 
 Response to organic cyclic compound (GO:0014070) 8 2.33 2.35E-02 
 Maturation of 5.8S rRNA (GO:0000460) 2 8.81 2.39E-02 
 Regulation of sprouting angiogenesis (GO:1903670) 2 8.81 2.39E-02 
 Cellular amino acid catabolic process (GO:0009063) 3 4.97 2.43E-02 
 Regulation of cell-matrix adhesion (GO:0001952) 3 4.92 2.51E-02 
 Regulation of cell aging (GO:0090342) 2 8.54 2.52E-02 
 Regulation of developmental growth (GO:0048638) 5 3.06 2.56E-02 
 Small molecule catabolic process (GO:0044282) 5 3.05 2.61E-02 
 Positive regulation of cell development (GO:0010720) 6 2.69 2.61E-02 
 Cardiovascular system development (GO:0072358) 7 2.45 2.64E-02 
 Endothelial cell development (GO:0001885) 2 8.29 2.66E-02 
 Developmental pigmentation (GO:0048066) 2 8.29 2.66E-02 
 Negative regulation of myeloid leukocyte differentiation 
(GO:0002762) 
2 8.29 2.66E-02 
 Second-messenger-mediated signaling (GO:0019932) 4 3.61 2.68E-02 
 Response to oxygen levels (GO:0070482) 4 3.59 2.73E-02 
 Positive regulation of cell morphogenesis involved in 
differentiation (GO:0010770) 
3 4.75 2.73E-02 
 Regulation of secretion (GO:0051046) 8 2.26 2.75E-02 
 Regulation of lipid storage (GO:0010883) 2 8.05 2.80E-02 
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 Table A.1 continued      
 GO biological process complete #genes FE P-value 
 Positive regulation of calcium ion transport into cytosol 
(GO:0010524) 
2 8.05 2.80E-02 
 Positive regulation of organelle organization 
(GO:0010638) 
8 2.25 2.83E-02 
 Positive regulation of secretion by cell (GO:1903532) 5 2.96 2.91E-02 
 Regulation of cellular component organization 
(GO:0051128) 
21 1.6 3.01E-02 
 Cellular response to organic cyclic compound 
(GO:0071407) 
6 2.59 3.09E-02 
 Positive regulation of cell-matrix adhesion (GO:0001954) 2 7.42 3.23E-02 
 Regulation of cell differentiation (GO:0045595) 15 1.75 3.29E-02 
 Ras protein signal transduction (GO:0007265) 3 4.4 3.29E-02 
 Regulation of substrate adhesion-dependent cell spreading 
(GO:1900024) 
2 7.23 3.38E-02 
 Substrate adhesion-dependent cell spreading 
(GO:0034446) 
2 7.23 3.38E-02 
 Positive regulation of peptide secretion (GO:0002793) 4 3.34 3.42E-02 
 Positive regulation of epithelial cell migration 
(GO:0010634) 
3 4.31 3.46E-02 
 Positive regulation of DNA replication (GO:0045740) 2 7.05 3.53E-02 
 Positive regulation of stress fiber assembly (GO:0051496) 2 7.05 3.53E-02 
 Labyrinthine layer development (GO:0060711) 2 7.05 3.53E-02 
 Regulation of lipid localization (GO:1905952) 3 4.23 3.64E-02 
 Negative regulation of cell projection organization 
(GO:0031345) 
3 4.23 3.64E-02 
 Positive regulation of intracellular signal transduction 
(GO:1902533) 
10 1.99 3.66E-02 
 Positive regulation of secretion (GO:0051047) 5 2.77 3.67E-02 
 Cellular pigmentation (GO:0033059) 2 6.88 3.69E-02 
 Positive regulation of lipid transport (GO:0032370) 2 6.88 3.69E-02 
 Organic acid catabolic process (GO:0016054) 4 3.24 3.74E-02 
 Carboxylic acid catabolic process (GO:0046395) 4 3.24 3.74E-02 
 Positive regulation of molecular function (GO:0044093) 16 1.74 3.80E-02 
 Intracellular receptor signaling pathway (GO:0030522) 3 4.15 3.82E-02 
 Glucose transport (GO:0015758) 2 6.71 3.85E-02 
 Regulation of cell development (GO:0060284) 9 2.19 3.86E-02 
 Regulation of peptide transport (GO:0090087) 9 2.19 3.86E-02 
 I-kappab kinase/NF-kappab signaling (GO:0007249) 2 6.56 4.01E-02 
 Regulation of ubiquitin-protein transferase activity 
(GO:0051438) 
2 6.56 4.01E-02 
 Negative regulation of nervous system development 
(GO:0051961) 
4 3.15 4.07E-02 
 Cellular amino acid metabolic process (GO:0006520) 5 2.69 4.09E-02 
 Regulation of cell growth (GO:0001558) 5 2.69 4.09E-02 
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 Table A.1 continued      
 GO biological process complete #genes FE P-value 
 Response to dsRNA (GO:0043331) 3 4.03 4.10E-02 
 Negative regulation of BMP signaling pathway 
(GO:0030514) 
2 6.41 4.17E-02 
 Posttranscriptional gene silencing by RNA (GO:0035194) 2 6.41 4.17E-02 
 Lymphocyte homeostasis (GO:0002260) 2 6.26 4.34E-02 
 Peptidyl-tyrosine autophosphorylation (GO:0038083) 2 6.26 4.34E-02 
 Cellular response to dsRNA (GO:0071359) 2 6.26 4.34E-02 
 Posttranscriptional gene silencing (GO:0016441) 2 6.26 4.34E-02 
 Negative regulation of I-kappab kinase/NF-kappab 
signaling (GO:0043124) 
2 6.26 4.34E-02 
 Hexose transport (GO:0008645) 2 6.26 4.34E-02 
 Lymphocyte migration (GO:0072676) 2 6.26 4.34E-02 
 Regulation of growth (GO:0040008) 7 2.19 4.39E-02 
 Cell proliferation (GO:0008283) 7 2.19 4.39E-02 
 Regulation of hemopoiesis (GO:1903706) 5 2.63 4.43E-02 
 Regulation of cell size (GO:0008361) 3 3.88 4.48E-02 
 Regulation of dendrite morphogenesis (GO:0048814) 2 6.13 4.50E-02 
 Protein localization to membrane (GO:0072657) 5 2.6 4.61E-02 
 Positive regulation of neuron differentiation 
(GO:0045666) 
4 3.01 4.64E-02 
 Positive regulation of MAPK cascade (GO:0043410) 6 2.34 4.64E-02 
 Monosaccharide transport (GO:0015749) 2 6 4.67E-02 
 Protein processing (GO:0016485) 3 3.81 4.68E-02 
 Cell differentiation (GO:0030154) 27 1.45 4.69E-02 
 Cellular response to molecule of bacterial origin 
(GO:0071219) 
3 3.71 4.99E-02 
Effect of sex 
 Translation (GO:0006412) 101 5.84 6.58E-42 
 Peptide biosynthetic process (GO:0043043) 101 5.64 8.81E-41 
 Amide biosynthetic process (GO:0043604) 103 5.09 3.67E-38 
 Peptide metabolic process (GO:0006518) 103 4.8 3.40E-36 
 Cellular amide metabolic process (GO:0043603) 106 4.08 7.70E-32 
 Cellular macromolecule biosynthetic process 
(GO:0034645) 
181 2.21 4.73E-23 
 Macromolecule biosynthetic process (GO:0009059) 181 2.17 1.99E-22 
 Organonitrogen compound biosynthetic process 
(GO:1901566) 
125 2.68 4.22E-22 
 Cellular nitrogen compound biosynthetic process 
(GO:0044271) 
165 2.11 4.11E-19 
 Cellular macromolecule metabolic process (GO:0044260) 293 1.62 1.85E-18 
 Cellular protein metabolic process (GO:0044267) 213 1.84 3.63E-18 
 Organic substance biosynthetic process (GO:1901576) 203 1.8 2.37E-16 
 Cellular nitrogen compound metabolic process 
(GO:0034641) 
232 1.7 3.41E-16 
99 
 Table A.1 continued      
 GO biological process complete #genes FE P-value 
 Cellular biosynthetic process (GO:0044249) 198 1.8 9.94E-16 
 Biosynthetic process (GO:0009058) 204 1.76 1.74E-15 
 Protein metabolic process (GO:0019538) 232 1.64 1.84E-14 
 Gene expression (GO:0010467) 168 1.85 3.42E-14 
 Organelle organization (GO:0006996) 178 1.74 6.55E-13 
 Macromolecule metabolic process (GO:0043170) 320 1.42 2.33E-12 
 Cellular component organization or biogenesis 
(GO:0071840) 
252 1.52 2.74E-12 
 Ribosome biogenesis (GO:0042254) 37 3.65 1.55E-10 
 Ribosome assembly (GO:0042255) 19 7.13 4.22E-10 
 Primary metabolic process (GO:0044238) 359 1.32 9.79E-10 
 Cellular component organization (GO:0016043) 233 1.47 9.91E-10 
 Nitrogen compound metabolic process (GO:0006807) 335 1.33 1.42E-09 
 Organonitrogen compound metabolic process 
(GO:1901564) 
249 1.43 2.09E-09 
 Ribonucleoprotein complex biogenesis (GO:0022613) 44 2.89 2.55E-09 
 Ribosomal large subunit biogenesis (GO:0042273) 20 5.73 3.88E-09 
 Cellular metabolic process (GO:0044237) 348 1.3 1.69E-08 
 Organic substance metabolic process (GO:0071704) 366 1.28 1.79E-08 
 Regulation of cell cycle (GO:0051726) 66 2.13 3.68E-08 
 Cellular process (GO:0009987) 588 1.15 6.77E-08 
 Cell cycle process (GO:0022402) 55 2.26 8.85E-08 
 Mitotic cell cycle process (GO:1903047) 38 2.74 1.12E-07 
 Cellular component biogenesis (GO:0044085) 126 1.63 1.30E-07 
 Cytoskeleton organization (GO:0007010) 67 2.05 1.36E-07 
 Ribonucleoprotein complex subunit organization 
(GO:0071826) 
28 3.33 1.50E-07 
 Mitotic cell cycle (GO:0000278) 40 2.57 2.87E-07 
 Cell cycle (GO:0007049) 64 2.03 3.68E-07 
 Ribosomal large subunit assembly (GO:0000027) 12 7.44 4.85E-07 
 Cytoplasmic translation (GO:0002181) 15 5.55 4.85E-07 
 Ribonucleoprotein complex assembly (GO:0022618) 26 3.27 5.78E-07 
 Metabolic process (GO:0008152) 378 1.22 1.93E-06 
 Spindle organization (GO:0007051) 18 4.03 2.31E-06 
 DNA metabolic process (GO:0006259) 48 2.17 2.34E-06 
 Cellular response to interleukin-4 (GO:0071353) 8 11.22 3.41E-06 
 Translational elongation (GO:0006414) 10 7.4 4.53E-06 
 Response to interleukin-4 (GO:0070670) 8 10.15 6.18E-06 
 Regulation of cell cycle process (GO:0010564) 39 2.24 8.86E-06 
 Cellular response to DNA damage stimulus 
(GO:0006974) 
45 2.09 9.40E-06 
 Chromosome segregation (GO:0007059) 25 2.81 1.08E-05 
 DNA-dependent DNA replication (GO:0006261) 15 4.08 1.39E-05 
 Nuclear division (GO:0000280) 25 2.74 1.59E-05 
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 Table A.1 continued      
 GO biological process complete #genes FE P-value 
 Ribosomal small subunit biogenesis (GO:0042274) 13 4.62 1.62E-05 
 Mitotic nuclear division (GO:0140014) 17 3.57 1.85E-05 
 Microtubule-based process (GO:0007017) 42 2.09 2.13E-05 
 Cellular component assembly (GO:0022607) 106 1.52 2.78E-05 
 Sister chromatid segregation (GO:0000819) 16 3.61 2.81E-05 
 DNA replication (GO:0006260) 18 3.26 3.13E-05 
 Chromosome organization (GO:0051276) 61 1.78 3.13E-05 
 Biological_process (GO:0008150) 699 1.07 3.31E-05 
 Positive regulation of biological process (GO:0048518) 219 1.3 3.70E-05 
 Organelle assembly (GO:0070925) 42 2.01 4.90E-05 
 DNA repair (GO:0006281) 31 2.28 5.44E-05 
 Macromolecular complex subunit organization 
(GO:0043933) 
80 1.61 6.09E-05 
 Regulation of immune system process (GO:0002682) 60 1.74 6.97E-05 
 Nuclear chromosome segregation (GO:0098813) 20 2.82 7.66E-05 
 Positive regulation of cellular process (GO:0048522) 198 1.3 8.62E-05 
 Mitotic spindle organization (GO:0007052) 11 4.51 8.68E-05 
 Organelle fission (GO:0048285) 25 2.49 8.89E-05 
 Regulation of mitotic cell cycle (GO:0007346) 34 2.12 1.14E-04 
 Mitotic sister chromatid segregation (GO:0000070) 13 3.73 1.18E-04 
 Regulation of small GTPase mediated signal transduction 
(GO:0051056) 
22 2.56 1.26E-04 
 Response to stress (GO:0006950) 124 1.41 1.56E-04 
 Regulation of lymphocyte activation (GO:0051249) 27 2.3 1.69E-04 
 rRNA metabolic process (GO:0016072) 19 2.72 1.74E-04 
 Microtubule cytoskeleton organization involved in mitosis 
(GO:1902850) 
12 3.76 1.96E-04 
 Microtubule cytoskeleton organization (GO:0000226) 30 2.16 1.98E-04 
#genes: number of genes associated with the GO term in the list of differentially expressed 
genes (DEG, q-value < 0.05) 
FE: Fold Enrichment  
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Table 0.2 Gene set enrichment analysis for blood tissue  
 GO biological process complete #genes FE P-value 
Effect of weaning  
 Translation (GO:0006412) 101 5.84 6.58E-42 
 Peptide biosynthetic process (GO:0043043) 101 5.64 8.81E-41 
 Amide biosynthetic process (GO:0043604) 103 5.09 3.67E-38 
 Peptide metabolic process (GO:0006518) 103 4.8 3.40E-36 
 Cellular amide metabolic process (GO:0043603) 106 4.08 7.70E-32 
 Cellular macromolecule biosynthetic process 
(GO:0034645) 
181 2.21 4.73E-23 
 Macromolecule biosynthetic process (GO:0009059) 181 2.17 1.99E-22 
 Organonitrogen compound biosynthetic process 
(GO:1901566) 
125 2.68 4.22E-22 
 Cellular nitrogen compound biosynthetic process 
(GO:0044271) 
165 2.11 4.11E-19 
 Cellular macromolecule metabolic process 
(GO:0044260) 
293 1.62 1.85E-18 
 Cellular protein metabolic process (GO:0044267) 213 1.84 3.63E-18 
 Organic substance biosynthetic process (GO:1901576) 203 1.8 2.37E-16 
 Cellular nitrogen compound metabolic process 
(GO:0034641) 
232 1.7 3.41E-16 
 Cellular biosynthetic process (GO:0044249) 198 1.8 9.94E-16 
 Biosynthetic process (GO:0009058) 204 1.76 1.74E-15 
 Protein metabolic process (GO:0019538) 232 1.64 1.84E-14 
 Gene expression (GO:0010467) 168 1.85 3.42E-14 
 Organelle organization (GO:0006996) 178 1.74 6.55E-13 
 Macromolecule metabolic process (GO:0043170) 320 1.42 2.33E-12 
 Cellular component organization or biogenesis 
(GO:0071840) 
252 1.52 2.74E-12 
 Ribosome biogenesis (GO:0042254) 37 3.65 1.55E-10 
 Ribosome assembly (GO:0042255) 19 7.13 4.22E-10 
 Primary metabolic process (GO:0044238) 359 1.32 9.79E-10 
 Cellular component organization (GO:0016043) 233 1.47 9.91E-10 
 Nitrogen compound metabolic process (GO:0006807) 335 1.33 1.42E-09 
 Organonitrogen compound metabolic process 
(GO:1901564) 
249 1.43 2.09E-09 
 Ribonucleoprotein complex biogenesis (GO:0022613) 44 2.89 2.55E-09 
 Ribosomal large subunit biogenesis (GO:0042273) 20 5.73 3.88E-09 
 Cellular metabolic process (GO:0044237) 348 1.3 1.69E-08 
 Organic substance metabolic process (GO:0071704) 366 1.28 1.79E-08 
 Regulation of cell cycle (GO:0051726) 66 2.13 3.68E-08 
 Cellular process (GO:0009987) 588 1.15 6.77E-08 
 Cell cycle process (GO:0022402) 55 2.26 8.85E-08 
 Mitotic cell cycle process (GO:1903047) 38 2.74 1.12E-07 
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 Table A.2 continued      
 GO biological process complete #genes FE P-value 
 Cellular component biogenesis (GO:0044085) 126 1.63 1.30E-07 
 Cytoskeleton organization (GO:0007010) 67 2.05 1.36E-07 
 Ribonucleoprotein complex subunit organization 
(GO:0071826) 
28 3.33 1.50E-07 
 Mitotic cell cycle (GO:0000278) 40 2.57 2.87E-07 
 Cell cycle (GO:0007049) 64 2.03 3.68E-07 
 Ribosomal large subunit assembly (GO:0000027) 12 7.44 4.85E-07 
 Cytoplasmic translation (GO:0002181) 15 5.55 4.85E-07 
 Ribonucleoprotein complex assembly (GO:0022618) 26 3.27 5.78E-07 
 Metabolic process (GO:0008152) 378 1.22 1.93E-06 
 Spindle organization (GO:0007051) 18 4.03 2.31E-06 
 DNA metabolic process (GO:0006259) 48 2.17 2.34E-06 
 Cellular response to interleukin-4 (GO:0071353) 8 11.22 3.41E-06 
 Translational elongation (GO:0006414) 10 7.4 4.53E-06 
 Response to interleukin-4 (GO:0070670) 8 10.15 6.18E-06 
 Regulation of cell cycle process (GO:0010564) 39 2.24 8.86E-06 
 Cellular response to DNA damage stimulus 
(GO:0006974) 
45 2.09 9.40E-06 
 Chromosome segregation (GO:0007059) 25 2.81 1.08E-05 
 DNA-dependent DNA replication (GO:0006261) 15 4.08 1.39E-05 
 Nuclear division (GO:0000280) 25 2.74 1.59E-05 
 Ribosomal small subunit biogenesis (GO:0042274) 13 4.62 1.62E-05 
 Mitotic nuclear division (GO:0140014) 17 3.57 1.85E-05 
 Microtubule-based process (GO:0007017) 42 2.09 2.13E-05 
 Cellular component assembly (GO:0022607) 106 1.52 2.78E-05 
 Sister chromatid segregation (GO:0000819) 16 3.61 2.81E-05 
 DNA replication (GO:0006260) 18 3.26 3.13E-05 
 Chromosome organization (GO:0051276) 61 1.78 3.13E-05 
 Biological_process (GO:0008150) 699 1.07 3.31E-05 
 Positive regulation of biological process 
(GO:0048518) 
219 1.3 3.70E-05 
 Organelle assembly (GO:0070925) 42 2.01 4.90E-05 
 DNA repair (GO:0006281) 31 2.28 5.44E-05 
 Macromolecular complex subunit organization 
(GO:0043933) 
80 1.61 6.09E-05 
 Regulation of immune system process (GO:0002682) 60 1.74 6.97E-05 
 Nuclear chromosome segregation (GO:0098813) 20 2.82 7.66E-05 
 Positive regulation of cellular process (GO:0048522) 198 1.3 8.62E-05 
 Mitotic spindle organization (GO:0007052) 11 4.51 8.68E-05 
 Organelle fission (GO:0048285) 25 2.49 8.89E-05 
 Regulation of mitotic cell cycle (GO:0007346) 34 2.12 1.14E-04 
 Mitotic sister chromatid segregation (GO:0000070) 13 3.73 1.18E-04 
 Regulation of small GTPase mediated signal 
transduction (GO:0051056) 
22 2.56 1.26E-04 
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 Response to stress (GO:0006950) 124 1.41 1.56E-04 
 Regulation of lymphocyte activation (GO:0051249) 27 2.3 1.69E-04 
 rRNA metabolic process (GO:0016072) 19 2.72 1.74E-04 
 Microtubule cytoskeleton organization involved in 
mitosis (GO:1902850) 
12 3.76 1.96E-04 
 Microtubule cytoskeleton organization (GO:0000226) 30 2.16 1.98E-04 
 Positive regulation of response to stimulus 
(GO:0048584) 
86 1.52 2.07E-04 
 Macromolecular complex disassembly (GO:0032984) 12 3.55 3.16E-04 
 Positive regulation of response to stimulus 
(GO:0048584) 
86 1.52 2.07E-04 
 Macromolecular complex disassembly (GO:0032984) 12 3.55 3.16E-04 
Effect of vaccination 
 Localization (GO:0051179) 141 1.61 3.46E-09 
 Establishment of localization (GO:0051234) 110 1.6 6.83E-07 
 Immune system process (GO:0002376) 58 1.93 2.65E-06 
 Transport (GO:0006810) 104 1.57 3.50E-06 
 Positive regulation of gtpase activity (GO:0043547) 22 3.18 4.20E-06 
 Cellular response to chemical stimulus (GO:0070887) 67 1.75 1.25E-05 
 Regulation of gtpase activity (GO:0043087) 23 2.87 1.27E-05 
 Regulation of response to stimulus (GO:0048583) 97 1.54 2.14E-05 
 Positive regulation of response to stimulus 
(GO:0048584) 
56 1.78 3.82E-05 
 Positive regulation of hydrolase activity 
(GO:0051345) 
28 2.4 3.93E-05 
 Cellular response to organic substance (GO:0071310) 55 1.77 5.19E-05 
 Cell differentiation (GO:0030154) 84 1.53 8.59E-05 
 Regulation of response to external stimulus 
(GO:0032101) 
26 2.35 9.76E-05 
 Transition metal ion transport (GO:0000041) 9 5.07 1.32E-04 
 Cellular homeostasis (GO:0019725) 28 2.24 1.36E-04 
 Developmental process (GO:0032502) 118 1.39 1.65E-04 
 Regulation of hydrolase activity (GO:0051336) 40 1.92 1.71E-04 
 Myeloid leukocyte activation (GO:0002274) 8 5.47 1.93E-04 
 Positive regulation of response to external stimulus 
(GO:0032103) 
14 3.22 2.06E-04 
 Regulation of signaling (GO:0023051) 83 1.5 2.22E-04 
 Regulation of signal transduction (GO:0009966) 77 1.53 2.22E-04 
 Regulation of localization (GO:0032879) 67 1.59 2.35E-04 
 Cellular developmental process (GO:0048869) 84 1.49 2.42E-04 
 Copper ion transport (GO:0006825) 4 15.97 2.58E-04 
 Substrate adhesion-dependent cell spreading 
(GO:0034446) 
6 7.37 2.93E-04 
 Iron ion transmembrane transport (GO:0034755) 4 14.74 3.32E-04 
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 Positive regulation of catalytic activity (GO:0043085) 40 1.85 3.47E-04 
 Transmembrane transport (GO:0055085) 42 1.81 3.57E-04 
 Regulation of actin cytoskeleton reorganization 
(GO:2000249) 
5 9.21 3.83E-04 
 Regulation of immune system process (GO:0002682) 36 1.88 3.97E-04 
 Regulation of response to stress (GO:0080134) 36 1.88 4.02E-04 
 Retina vasculature development in camera-type eye 
(GO:0061298) 
4 13.69 4.21E-04 
 Regulation of catalytic activity (GO:0050790) 61 1.59 4.75E-04 
 Tissue remodeling (GO:0048771) 8 4.73 4.78E-04 
 Regulation of cell communication (GO:0010646) 81 1.48 4.78E-04 
 Leukocyte migration (GO:0050900) 11 3.51 4.95E-04 
 Iron ion transport (GO:0006826) 6 6.53 5.25E-04 
 Regulation of endocytosis (GO:0030100) 11 3.47 5.49E-04 
 Regulation of cell motility (GO:2000145) 27 2.09 5.50E-04 
 Cellular response to oxygen-containing compound 
(GO:1901701) 
25 2.12 5.89E-04 
 Response to wounding (GO:0009611) 15 2.75 6.04E-04 
 Positive regulation of molecular function 
(GO:0044093) 
46 1.7 6.32E-04 
 Myeloid leukocyte differentiation (GO:0002573) 8 4.51 6.42E-04 
 Homeostatic process (GO:0042592) 42 1.76 6.55E-04 
 Regulation of molecular function (GO:0065009) 84 1.45 6.60E-04 
 Regulation of cell migration (GO:0030334) 26 2.11 6.89E-04 
 Response to stress (GO:0006950) 73 1.49 7.64E-04 
 Ion transport (GO:0006811) 43 1.73 8.25E-04 
 Cation transport (GO:0006812) 31 1.91 8.38E-04 
 Metal ion transport (GO:0030001) 24 2.09 8.82E-04 
 Cell activation (GO:0001775) 21 2.22 8.82E-04 
 Cell migration (GO:0016477) 26 2.04 9.03E-04 
 Plasma membrane repair (GO:0001778) 3 20.53 9.16E-04 
 Cellular response to macrophage colony-stimulating 
factor stimulus (GO:0036006) 
3 20.53 9.16E-04 
 Response to macrophage colony-stimulating factor 
(GO:0036005) 
3 20.53 9.16E-04 
 Transition metal ion homeostasis (GO:0055076) 9 3.82 9.19E-04 
 Regulation of cellular component movement 
(GO:0051270) 
28 1.99 9.28E-04 
 Inflammatory response (GO:0006954) 16 2.52 9.83E-04 
 Regulation of biological quality (GO:0065008) 85 1.42 1.00E-03 
 Wound healing (GO:0042060) 13 2.83 1.08E-03 
 Negative regulation of alpha-beta T cell activation 
(GO:0046636) 
4 10.08 1.12E-03 
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 Positive regulation of signal transduction 
(GO:0009967) 
40 1.74 1.13E-03 
 
 Cellular chemical homeostasis (GO:0055082) 22 2.17 1.14E-03 
 Cellular response to iron ion (GO:0071281) 3 17.96 1.24E-03 
 Iron ion import across plasma membrane 
(GO:0098711) 
3 17.96 1.24E-03 
 T cell chemotaxis (GO:0010818) 3 17.96 1.24E-03 
 Multicellular organismal iron ion homeostasis 
(GO:0060586) 
3 17.96 1.24E-03 
 Positive regulation of signaling (GO:0023056) 42 1.68 1.29E-03 
 Leukocyte activation (GO:0045321) 18 2.36 1.36E-03 
 Defense response (GO:0006952) 32 1.83 1.37E-03 
 Chemical homeostasis (GO:0048878) 29 1.93 1.37E-03 
 Regulated exocytosis (GO:0045055) 8 3.95 1.42E-03 
 Inorganic cation transmembrane transport 
(GO:0098662) 
22 2.08 1.62E-03 
 Positive regulation of endoplasmic reticulum unfolded 
protein response (GO:1900103) 
3 15.97 1.63E-03 
 Response to organic substance (GO:0010033) 59 1.52 1.69E-03 
 Regulation of locomotion (GO:0040012) 27 1.91 1.70E-03 
 Response to cytokine (GO:0034097) 26 1.97 1.75E-03 
 Regulation of intracellular signal transduction 
(GO:1902531) 
46 1.61 1.84E-03 
 Leukocyte differentiation (GO:0002521) 15 2.43 1.99E-03 
 Endomembrane system organization (GO:0010256) 14 2.51 2.06E-03 
 Cation transmembrane transport (GO:0098655) 24 1.96 2.17E-03 
 Regulation of vesicle-mediated transport 
(GO:0060627) 
17 2.31 2.18E-03 
 Positive regulation of cellular component movement 
(GO:0051272) 
17 2.3 2.22E-03 
 Small GTPase mediated signal transduction 
(GO:0007264) 
12 2.72 2.24E-03 
 Locomotion (GO:0040011) 32 1.78 2.32E-03 
 Positive regulation of cellular process (GO:0048522) 111 1.31 2.35E-03 
 Organic substance transport (GO:0071702) 50 1.55 2.37E-03 
 Immune response (GO:0006955) 30 1.8 2.42E-03 
 Divalent metal ion export (GO:0070839) 2 47.9 2.44E-03 
 Positive regulation of lysosomal protein catabolic 
process (GO:1905167) 
2 47.9 2.44E-03 
 Immune system development (GO:0002520) 23 1.99 2.45E-03 
 Positive regulation of cell communication 
(GO:0010647) 
41 1.65 2.46E-03 
 Plasma membrane organization (GO:0007009) 6 4.71 2.46E-03 
 Cellular copper ion homeostasis (GO:0006878) 3 13.06 2.61E-03 
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 Iron ion import (GO:0097286) 3 13.06 2.61E-03 
 Response to tumor necrosis factor (GO:0034612) 9 3.24 2.64E-03 
 Divalent metal ion transport (GO:0070838) 13 2.53 2.75E-03 
 Anatomical structure development (GO:0048856) 105 1.32 2.77E-03 
 Cellular transition metal ion homeostasis 
(GO:0046916) 
7 3.94 2.81E-03 
 Divalent inorganic cation transport (GO:0072511) 13 2.52 2.85E-03 
 Organic anion transport (GO:0015711) 17 2.22 2.88E-03 
 Cellular response to cytokine stimulus (GO:0071345) 23 1.95 2.92E-03 
 Intracellular pH reduction (GO:0051452) 4 7.37 3.10E-03 
 Carbohydrate derivative catabolic process 
(GO:1901136) 
8 3.45 3.13E-03 
 Negative regulation of leukocyte activation 
(GO:0002695) 
8 3.45 3.13E-03 
 Hematopoietic or lymphoid organ development 
(GO:0048534) 
22 1.99 3.17E-03 
 Regulation of cholesterol homeostasis (GO:2000188) 3 11.98 3.22E-03 
 Negative regulation of type 2 immune response 
(GO:0002829) 
3 11.98 3.22E-03 
 Positive regulation of protein metabolic process 
(GO:0051247) 
42 1.6 3.31E-03 
 Response to oxygen-containing compound 
(GO:1901700) 
31 1.74 3.34E-03 
 Inorganic ion transmembrane transport (GO:0098660) 24 1.94 3.35E-03 
 Vesicle fusion (GO:0006906) 7 3.81 3.37E-03 
 Cellular monovalent inorganic cation homeostasis 
(GO:0030004) 
7 3.81 3.37E-03 
 Positive regulation of biological process 
(GO:0048518) 
120 1.28 3.49E-03 
 Negative regulation of leukocyte mediated immunity 
(GO:0002704) 
4 7.1 3.51E-03 
 Organelle membrane fusion (GO:0090174) 7 3.77 3.57E-03 
 Animal organ development (GO:0048513) 66 1.43 3.71E-03 
 Regulation of MAPK cascade (GO:0043408) 22 1.94 3.82E-03 
 Myeloid cell differentiation (GO:0030099) 10 2.83 3.90E-03 
 Cellular ion homeostasis (GO:0006873) 19 2.06 3.95E-03 
 Inorganic ion homeostasis (GO:0098771) 21 2.02 3.97E-03 
 Ion transmembrane transport (GO:0034220) 30 1.76 3.98E-03 
 Purine nucleobase transport (GO:0006863) 2 31.93 4.01E-03 
 Wnt signaling pathway, calcium modulating pathway 
(GO:0007223) 
2 31.93 4.01E-03 
 Purine nucleobase transmembrane transport 
(GO:1904823) 
2 31.93 4.01E-03 
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 Positive regulation of amyloid-beta clearance 
(GO:1900223) 
2 31.93 4.01E-03 
 Copper ion transmembrane transport (GO:0035434) 2 31.93 4.01E-03 
 Pyrimidine nucleobase transport (GO:0015855) 2 31.93 4.01E-03 
 Nucleobase transport (GO:0015851) 2 31.93 4.01E-03 
 Positive regulation of protein catabolic process in the 
vacuole (GO:1904352) 
2 31.93 4.01E-03 
 Response to muscle activity involved in regulation of 
muscle adaptation (GO:0014873) 
2 31.93 4.01E-03 
 Response to interferon-gamma (GO:0034341) 6 4.23 4.06E-03 
 Positive regulation of cell motility (GO:2000147) 16 2.2 4.11E-03 
 Regulation of small GTPase mediated signal 
transduction (GO:0051056) 
12 2.51 4.20E-03 
 Regulation of leukocyte chemotaxis (GO:0002688) 7 3.64 4.23E-03 
 Ph reduction (GO:0045851) 4 6.61 4.42E-03 
 Import into cell (GO:0098657) 18 2.12 4.51E-03 
 Positive regulation of ERK1 and ERK2 cascade 
(GO:0070374) 
9 2.97 4.51E-03 
 Regulation of Ras protein signal transduction 
(GO:0046578) 
11 2.61 4.59E-03 
 Copper ion homeostasis (GO:0055070) 3 10.26 4.67E-03 
 Localization of cell (GO:0051674) 26 1.79 4.74E-03 
 Cell motility (GO:0048870) 26 1.79 4.74E-03 
 Ion homeostasis (GO:0050801) 21 1.94 4.89E-03 
 Membrane organization (GO:0061024) 21 1.94 4.89E-03 
 Membrane fusion (GO:0061025) 9 2.93 4.91E-03 
 Drug transport (GO:0015893) 8 3.17 5.10E-03 
 Cell chemotaxis (GO:0060326) 9 2.91 5.11E-03 
 Regulation of ERK1 and ERK2 cascade 
(GO:0070372) 
11 2.56 5.26E-03 
 System development (GO:0048731) 86 1.34 5.29E-03 
 Biological regulation (GO:0065007) 262 1.13 5.35E-03 
 Myeloid dendritic cell differentiation (GO:0043011) 3 9.58 5.52E-03 
 T cell migration (GO:0072678) 3 9.58 5.52E-03 
 Anion transport (GO:0006820) 20 2 5.57E-03 
 Cation homeostasis (GO:0055080) 20 1.97 5.87E-03 
 Hemopoiesis (GO:0030097) 20 1.97 5.87E-03 
 Glycerol-3-phosphate biosynthetic process 
(GO:0046167) 
2 23.95 5.93E-03 
 Positive regulation of PERK-mediated unfolded 
protein response (GO:1903899) 
2 23.95 5.93E-03 
 Ferrous iron transmembrane transport (GO:1903874) 2 23.95 5.93E-03 
 Ferrous iron transport (GO:0015684) 2 23.95 5.93E-03 
 Cellular cation homeostasis (GO:0030003) 18 2.01 6.04E-03 
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 Osteoclast differentiation (GO:0030316) 4 5.99 6.06E-03 
 Negative regulation of cellular process (GO:0048523) 98 1.31 6.10E-03 
 Positive regulation of immune system process 
(GO:0002684) 
23 1.83 6.18E-03 
 Negative regulation of cell activation (GO:0050866) 8 3.04 6.39E-03 
 Response to iron ion (GO:0010039) 3 8.98 6.45E-03 
 Regulation of lymphocyte chemotaxis (GO:1901623) 3 8.98 6.45E-03 
 Regulation of endoplasmic reticulum unfolded protein 
response (GO:1900101) 
3 8.98 6.45E-03 
 Multicellular organism development (GO:0007275) 94 1.31 6.47E-03 
 Activation of cysteine-type endopeptidase activity 
involved in apoptotic process (GO:0006919) 
5 4.52 6.59E-03 
 Positive regulation of cell migration (GO:0030335) 15 2.14 6.63E-03 
 Synaptic vesicle cycle (GO:0099504) 6 3.78 6.70E-03 
 Positive regulation of inflammatory response 
(GO:0050729) 
6 3.78 6.70E-03 
 Receptor-mediated endocytosis (GO:0006898) 9 2.78 6.76E-03 
 Lysosome organization (GO:0007040) 5 4.44 7.08E-03 
 Lytic vacuole organization (GO:0080171) 5 4.44 7.08E-03 
 Leukocyte cell-cell adhesion (GO:0007159) 4 5.64 7.35E-03 
 Non-canonical Wnt signaling pathway (GO:0035567) 4 5.64 7.35E-03 
 Myeloid dendritic cell activation (GO:0001773) 3 8.45 7.48E-03 
 Negative regulation of cell junction assembly 
(GO:1901889) 
3 8.45 7.48E-03 
 Myeloid leukocyte migration (GO:0097529) 6 3.68 7.52E-03 
 Regulation of alpha-beta T cell activation 
(GO:0046634) 
5 4.35 7.60E-03 
 Forebrain generation of neurons (GO:0021872) 5 4.35 7.60E-03 
 Secretion by cell (GO:0032940) 14 2.19 7.78E-03 
 Regulation of cellular response to stress 
(GO:0080135) 
19 1.97 7.85E-03 
 Regulation of cellular pH (GO:0030641) 6 3.64 7.95E-03 
 Response to stimulus (GO:0050896) 170 1.19 8.06E-03 
 Mo-molybdopterin cofactor biosynthetic process 
(GO:0006777) 
2 19.16 8.19E-03 
 Virion attachment to host cell (GO:0019062) 2 19.16 8.19E-03 
 Hard palate development (GO:0060022) 2 19.16 8.19E-03 
 Adhesion of symbiont to host cell (GO:0044650) 2 19.16 8.19E-03 
 Regulation of lysosomal protein catabolic process 
(GO:1905165) 
2 19.16 8.19E-03 
 Negative regulation of macrophage activation 
(GO:0043031) 
2 19.16 8.19E-03 
 Copper ion import (GO:0015677) 2 19.16 8.19E-03 
 Neutrophil clearance (GO:0097350) 2 19.16 8.19E-03 
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 Amyloid-beta clearance (GO:0097242) 2 19.16 8.19E-03 
 Mo-molybdopterin cofactor metabolic process 
(GO:0019720) 
2 19.16 8.19E-03 
 Dichotomous subdivision of terminal units involved in 
salivary gland branching (GO:0060666) 
2 19.16 8.19E-03 
 Inactivation of MAPK activity (GO:0000188) 3 7.98 8.59E-03 
 Macrophage activation (GO:0042116) 3 7.98 8.59E-03 
 Endocytosis (GO:0006897) 16 2.1 8.79E-03 
 Bone remodeling (GO:0046849) 4 5.32 8.82E-03 
 Iron ion homeostasis (GO:0055072) 6 3.55 8.88E-03 
 Cellular response to lipid (GO:0071396) 14 2.14 8.90E-03 
 Monovalent inorganic cation homeostasis 
(GO:0055067) 
7 3.13 9.03E-03 
 Positive regulation of cellular protein metabolic 
process (GO:0032270) 
38 1.54 9.14E-03 
 Positive regulation of locomotion (GO:0040017) 16 2.06 9.41E-03 
 Organelle fusion (GO:0048284) 7 3.1 9.45E-03 
 Exocytosis (GO:0006887) 9 2.61 9.78E-03 
 Wnt signaling pathway, planar cell polarity pathway 
(GO:0060071) 
3 7.56 9.80E-03 
 Acetylcholine receptor signaling pathway 
(GO:0095500) 
3 7.56 9.80E-03 
 Positive regulation of antigen receptor-mediated 
signaling pathway (GO:0050857) 
3 7.56 9.80E-03 
 Cellular response to acetylcholine (GO:1905145) 3 7.56 9.80E-03 
 Response to acetylcholine (GO:1905144) 3 7.56 9.80E-03 
 Signal transduction involved in cellular response to 
ammonium ion (GO:1903831) 
3 7.56 9.80E-03 
 Negative regulation of adaptive immune response 
based on somatic recombination of immune receptors 
built from immunoglobulin superfamily domains 
(GO:0002823) 
3 7.56 9.80E-03 
 Regulation of antigen receptor-mediated signaling 
pathway (GO:0050854) 
4 5.04 1.05E-02 
 Lipid transport (GO:0006869) 11 2.31 1.05E-02 
 Vesicle organization (GO:0016050) 11 2.31 1.05E-02 
 Cellular defense response (GO:0006968) 2 15.97 1.08E-02 
 Negative regulation of endothelial cell differentiation 
(GO:0045602) 
2 15.97 1.08E-02 
 Adhesion of symbiont to host (GO:0044406) 2 15.97 1.08E-02 
 Prosthetic group metabolic process (GO:0051189) 2 15.97 1.08E-02 
 Molybdopterin cofactor metabolic process 
(GO:0043545) 
2 15.97 1.08E-02 
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 Regulation of skeletal muscle tissue regeneration 
(GO:0043416) 
2 15.97 1.08E-02 
 Positive regulation of skeletal muscle tissue 
regeneration (GO:0043415) 
2 15.97 1.08E-02 
 Regulation of protein catabolic process in the vacuole 
(GO:1904350) 
2 15.97 1.08E-02 
 Kidney vasculature morphogenesis (GO:0061439) 2 15.97 1.08E-02 
 Renal system vasculature morphogenesis 
(GO:0061438) 
2 15.97 1.08E-02 
 Negative regulation of T cell cytokine production 
(GO:0002725) 
2 15.97 1.08E-02 
 Vacuolar acidification (GO:0007035) 3 7.19 1.11E-02 
 Negative regulation of cytokine production involved in 
immune response (GO:0002719) 
3 7.19 1.11E-02 
 Negative regulation of lymphocyte mediated immunity 
(GO:0002707) 
3 7.19 1.11E-02 
 Establishment of organelle localization (GO:0051656) 13 2.16 1.14E-02 
 Secretion (GO:0046903) 16 1.97 1.17E-02 
 Calcium ion regulated exocytosis (GO:0017156) 5 3.86 1.20E-02 
 Granulocyte migration (GO:0097530) 5 3.86 1.20E-02 
 Positive regulation of endocytosis (GO:0045807) 6 3.3 1.21E-02 
 Positive regulation of defense response (GO:0031349) 10 2.37 1.22E-02 
 Purine-containing compound catabolic process 
(GO:0072523) 
4 4.79 1.23E-02 
 Regulation of pH (GO:0006885) 6 3.27 1.27E-02 
 Positive regulation of response to wounding 
(GO:1903036) 
4 4.67 1.33E-02 
 Positive regulation of protein kinase B signaling 
(GO:0051897) 
5 3.74 1.35E-02 
 Regulation of leukocyte migration (GO:0002685) 8 2.64 1.36E-02 
 Regulation of melanocyte differentiation 
(GO:0045634) 
2 13.69 1.37E-02 
 Neutrophil activation involved in immune response 
(GO:0002283) 
2 13.69 1.37E-02 
 Purine nucleobase catabolic process (GO:0006145) 2 13.69 1.37E-02 
 Arginine transport (GO:0015809) 2 13.69 1.37E-02 
 Regulation of PERK-mediated unfolded protein 
response (GO:1903897) 
2 13.69 1.37E-02 
 Response to stimulus involved in regulation of muscle 
adaptation (GO:0014874) 
2 13.69 1.37E-02 
 Lipid localization (GO:0010876) 12 2.23 1.37E-02 
 Negative regulation of biological process 
(GO:0048519) 
103 1.26 1.39E-02 
 Regulation of type 2 immune response (GO:0002828) 3 6.53 1.40E-02 
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 Negative regulation of adaptive immune response 
(GO:0002820) 
3 6.53 1.40E-02 
 Forebrain neuron development (GO:0021884) 3 6.53 1.40E-02 
 Regulation of granulocyte chemotaxis (GO:0071622) 4 4.56 1.43E-02 
 Cell activation involved in immune response 
(GO:0002263) 
8 2.61 1.46E-02 
 Regulation of chemotaxis (GO:0050920) 8 2.61 1.46E-02 
 Negative regulation of cellular component movement 
(GO:0051271) 
10 2.3 1.46E-02 
 Positive regulation of MAPK cascade (GO:0043410) 15 1.98 1.48E-02 
 Intracellular signal transduction (GO:0035556) 37 1.52 1.54E-02 
 Forebrain neuron differentiation (GO:0021879) 4 4.46 1.54E-02 
 Regulation of inflammatory response (GO:0050727) 10 2.28 1.55E-02 
 Regulation of cell junction assembly (GO:1901888) 5 3.57 1.60E-02 
 Cellular response to hypoxia (GO:0071456) 5 3.57 1.60E-02 
 Regulation of multicellular organismal process 
(GO:0051239) 
60 1.37 1.61E-02 
 Vesicle-mediated transport in synapse (GO:0099003) 6 3.09 1.61E-02 
 Cellular response to tumor necrosis factor 
(GO:0071356) 
7 2.77 1.63E-02 
 Fat cell differentiation (GO:0045444) 6 3.06 1.68E-02 
 Regulation of adaptive immune response based on 
somatic recombination of immune receptors built from 
immunoglobulin superfamily domains (GO:0002822) 
6 3.06 1.68E-02 
 Leukotriene biosynthetic process (GO:0019370) 2 11.98 1.68E-02 
 Glycerol-3-phosphate metabolic process 
(GO:0006072) 
2 11.98 1.68E-02 
 Regulation of pigment cell differentiation 
(GO:0050932) 
2 11.98 1.68E-02 
 Regulation of amyloid-beta clearance (GO:1900221) 2 11.98 1.68E-02 
 Neuron remodeling (GO:0016322) 2 11.98 1.68E-02 
 Granzyme-mediated apoptotic signaling pathway 
(GO:0008626) 
2 11.98 1.68E-02 
 Retina vasculature morphogenesis in camera-type eye 
(GO:0061299) 
2 11.98 1.68E-02 
 Type 2 immune response (GO:0042092) 2 11.98 1.68E-02 
 Dichotomous subdivision of an epithelial terminal unit 
(GO:0060600) 
2 11.98 1.68E-02 
 T-helper 17 cell differentiation (GO:0072539) 2 11.98 1.68E-02 
 T-helper 17 type immune response (GO:0072538) 2 11.98 1.68E-02 
 Purine-containing compound transmembrane transport 
(GO:0072530) 
2 11.98 1.68E-02 
 Icosanoid metabolic process (GO:0006690) 5 3.52 1.69E-02 
 Phospholipid transport (GO:0015914) 5 3.52 1.69E-02 
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 Regulation of endothelial cell differentiation 
(GO:0045601) 
3 5.99 1.73E-02 
 T cell mediated immunity (GO:0002456) 3 5.99 1.73E-02 
 Cellular response to vascular endothelial growth factor 
stimulus (GO:0035924) 
3 5.99 1.73E-02 
 Regulation of macrophage activation (GO:0043030) 3 5.99 1.73E-02 
 Endoplasmic reticulum unfolded protein response 
(GO:0030968) 
4 4.26 1.77E-02 
 Lymphocyte migration (GO:0072676) 4 4.26 1.77E-02 
 Cellular response to decreased oxygen levels 
(GO:0036294) 
5 3.47 1.78E-02 
 Positive regulation of peptidyl-tyrosine 
phosphorylation (GO:0050731) 
7 2.7 1.83E-02 
 Leukocyte chemotaxis (GO:0030595) 6 2.99 1.84E-02 
 Negative regulation of transcription by RNA 
polymerase II (GO:0000122) 
23 1.67 1.86E-02 
 Negative regulation of cell-substrate adhesion 
(GO:0010812) 
4 4.17 1.90E-02 
 Ameboidal-type cell migration (GO:0001667) 7 2.68 1.90E-02 
 Positive regulation of response to endoplasmic 
reticulum stress (GO:1905898) 
3 5.75 1.91E-02 
 Positive regulation of leukocyte migration 
(GO:0002687) 
6 2.96 1.92E-02 
 Leukocyte migration involved in inflammatory 
response (GO:0002523) 
2 10.64 2.03E-02 
 Alditol phosphate metabolic process (GO:0052646) 2 10.64 2.03E-02 
 SMAD protein import into nucleus (GO:0007184) 2 10.64 2.03E-02 
 Leukotriene metabolic process (GO:0006691) 2 10.64 2.03E-02 
 Negative regulation of protein autophosphorylation 
(GO:0031953) 
2 10.64 2.03E-02 
 Inhibition of cysteine-type endopeptidase activity 
involved in apoptotic process (GO:1990001) 
2 10.64 2.03E-02 
 Basic amino acid transport (GO:0015802) 2 10.64 2.03E-02 
 Positive regulation of triglyceride biosynthetic process 
(GO:0010867) 
2 10.64 2.03E-02 
 Regulation of skeletal muscle cell proliferation 
(GO:0014857) 
2 10.64 2.03E-02 
 Pyrimidine-containing compound transmembrane 
transport (GO:0072531) 
2 10.64 2.03E-02 
 Cellular carbohydrate metabolic process 
(GO:0044262) 
7 2.64 2.04E-02 
 Negative regulation of cell migration (GO:0030336) 9 2.29 2.05E-02 
 Signal transduction by p53 class mediator 
(GO:0072331) 
5 3.33 2.08E-02 
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 Positive regulation of leukocyte chemotaxis 
(GO:0002690) 
5 3.33 2.08E-02 
 Substantia nigra development (GO:0021762) 3 5.53 2.09E-02 
 Dendritic cell differentiation (GO:0097028) 3 5.53 2.09E-02 
 Negative regulation of production of molecular 
mediator of immune response (GO:0002701) 
3 5.53 2.09E-02 
 Regulation of defense response (GO:0031347) 16 1.9 2.11E-02 
 Tumor necrosis factor-mediated signaling pathway 
(GO:0033209) 
4 3.99 2.16E-02 
 Positive regulation of JAK-STAT cascade 
(GO:0046427) 
4 3.99 2.16E-02 
 Regulation of stress-activated MAPK cascade 
(GO:0032872) 
8 2.41 2.18E-02 
 Regulation of cellular component organization 
(GO:0051128) 
53 1.37 2.21E-02 
 Regulation of stress-activated protein kinase signaling 
cascade (GO:0070302) 
8 2.4 2.25E-02 
 Regulation of adaptive immune response 
(GO:0002819) 
6 2.85 2.27E-02 
 Negative regulation of neuron death (GO:1901215) 7 2.58 2.28E-02 
 Positive regulation of intracellular signal transduction 
(GO:1902533) 
24 1.63 2.29E-02 
 Blood vessel remodeling (GO:0001974) 3 5.32 2.29E-02 
 Regulation of T cell receptor signaling pathway 
(GO:0050856) 
3 5.32 2.29E-02 
 Regulation of epithelial cell apoptotic process 
(GO:1904035) 
4 3.91 2.30E-02 
 Regulation of cysteine-type endopeptidase activity 
involved in apoptotic process (GO:0043281) 
8 2.38 2.33E-02 
 Positive regulation of chemotaxis (GO:0050921) 6 2.82 2.36E-02 
 Chemotaxis (GO:0006935) 14 1.9 2.38E-02 
 Biological_process (GO:0008150) 382 1.06 2.39E-02 
 Nucleobase catabolic process (GO:0046113) 2 9.58 2.40E-02 
 Negative regulation of T-helper cell differentiation 
(GO:0045623) 
2 9.58 2.40E-02 
 T cell cytokine production (GO:0002369) 2 9.58 2.40E-02 
 Neutrophil homeostasis (GO:0001780) 2 9.58 2.40E-02 
 Export across plasma membrane (GO:0140115) 2 9.58 2.40E-02 
 Vacuolar proton-transporting V-type ATPpase 
complex assembly (GO:0070072) 
2 9.58 2.40E-02 
 Proton-transporting V-type ATPase complex assembly 
(GO:0070070) 
2 9.58 2.40E-02 
 Glial cell activation (GO:0061900) 2 9.58 2.40E-02 
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 Positive regulation of execution phase of apoptosis 
(GO:1900119) 
2 9.58 2.40E-02 
 Fibroblast migration (GO:0010761) 2 9.58 2.40E-02 
 Coronary vasculature morphogenesis (GO:0060977) 2 9.58 2.40E-02 
 Zymogen inhibition (GO:0097341) 2 9.58 2.40E-02 
 Inhibition of cysteine-type endopeptidase activity 
(GO:0097340) 
2 9.58 2.40E-02 
 Negative regulation of cell fate commitment 
(GO:0010454) 
2 9.58 2.40E-02 
 Phototransduction, visible light (GO:0007603) 2 9.58 2.40E-02 
 Regulation of ER to Golgi vesicle-mediated transport 
(GO:0060628) 
2 9.58 2.40E-02 
 Negative regulation of T cell mediated immunity 
(GO:0002710) 
2 9.58 2.40E-02 
 Positive regulation of cellular extravasation 
(GO:0002693) 
2 9.58 2.40E-02 
 Regulation of intracellular pH (GO:0051453) 5 3.19 2.41E-02 
 Taxis (GO:0042330) 14 1.89 2.41E-02 
 Positive regulation of STAT cascade (GO:1904894) 4 3.83 2.44E-02 
 Cellular response to unfolded protein (GO:0034620) 4 3.83 2.44E-02 
 Regulation of protein kinase B signaling 
(GO:0051896) 
6 2.79 2.46E-02 
 Negative regulation of protein processing 
(GO:0010955) 
3 5.13 2.50E-02 
 Adipose tissue development (GO:0060612) 3 5.13 2.50E-02 
 Negative regulation of protein maturation 
(GO:1903318) 
3 5.13 2.50E-02 
 Positive regulation of protein catabolic process 
(GO:0045732) 
8 2.34 2.55E-02 
 Regulation of intrinsic apoptotic signaling pathway 
(GO:2001242) 
7 2.5 2.61E-02 
 Negative regulation of intracellular signal transduction 
(GO:1902532) 
16 1.79 2.64E-02 
 Negative regulation of immune effector process 
(GO:0002698) 
5 3.11 2.64E-02 
 Negative regulation of neuron apoptotic process 
(GO:0043524) 
6 2.74 2.66E-02 
 Negative regulation of cell-matrix adhesion 
(GO:0001953) 
3 4.96 2.72E-02 
 Inorganic ion import across plasma membrane 
(GO:0099587) 
3 4.96 2.72E-02 
 Regulation of protein autophosphorylation 
(GO:0031952) 
3 4.96 2.72E-02 
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 Regulation of establishment of planar polarity 
(GO:0090175) 
3 4.96 2.72E-02 
 Inorganic cation import across plasma membrane 
(GO:0098659) 
3 4.96 2.72E-02 
 G2/M transition of mitotic cell cycle (GO:0000086) 3 4.96 2.72E-02 
 Negative regulation of developmental process 
(GO:0051093) 
23 1.64 2.78E-02 
 Cell-substrate adhesion (GO:0031589) 7 2.47 2.79E-02 
 Positive regulation of receptor recycling 
(GO:0001921) 
2 8.71 2.80E-02 
 Positive regulation of lymphocyte chemotaxis 
(GO:0140131) 
2 8.71 2.80E-02 
 Planar cell polarity pathway involved in neural tube 
closure (GO:0090179) 
2 8.71 2.80E-02 
 Negative regulation of CD4-positive, alpha-beta T cell 
differentiation (GO:0043371) 
2 8.71 2.80E-02 
 Regulation of cell proliferation (GO:0042127) 36 1.46 2.83E-02 
 Response to external stimulus (GO:0009605) 39 1.43 2.83E-02 
 Negative regulation of locomotion (GO:0040013) 10 2.19 2.85E-02 
 Response to abiotic stimulus (GO:0009628) 23 1.62 2.90E-02 
 Synaptic vesicle exocytosis (GO:0016079) 4 3.62 2.91E-02 
 Positive regulation of nitrogen compound metabolic 
process (GO:0051173) 
66 1.3 2.92E-02 
 Carbohydrate metabolic process (GO:0005975) 15 1.87 2.93E-02 
 Negative regulation of endocytosis (GO:0045806) 3 4.79 2.94E-02 
 Positive regulation of cellular protein catabolic process 
(GO:1903364) 
6 2.66 2.98E-02 
 Establishment of vesicle localization (GO:0051650) 7 2.43 2.98E-02 
 Regulation of protein metabolic process 
(GO:0051246) 
62 1.31 2.99E-02 
 Cellular response to interferon-gamma (GO:0071346) 4 3.55 3.08E-02 
 Response to lipid (GO:0033993) 17 1.77 3.10E-02 
 Regulation of transport (GO:0051049) 40 1.41 3.10E-02 
 Pigmentation (GO:0043473) 5 2.96 3.16E-02 
 Leukocyte mediated immunity (GO:0002443) 7 2.4 3.18E-02 
 Movement of cell or subcellular component 
(GO:0006928) 
31 1.48 3.18E-02 
 Cell cycle G2/M phase transition (GO:0044839) 3 4.64 3.18E-02 
 Positive regulation of gliogenesis (GO:0014015) 3 4.64 3.18E-02 
 Regulation of protein deacetylation (GO:0090311) 3 4.64 3.18E-02 
 Regulation of neutrophil chemotaxis (GO:0090022) 3 4.64 3.18E-02 
 Positive regulation of cellular metabolic process 
(GO:0031325) 
68 1.29 3.19E-02 
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 Regulation of antigen processing and presentation 
(GO:0002577) 
2 7.98 3.23E-02 
 Mononuclear cell differentiation (GO:1903131) 2 7.98 3.23E-02 
 Phospholipase C-activating dopamine receptor 
signaling pathway (GO:0060158) 
2 7.98 3.23E-02 
 Negative regulation of focal adhesion assembly 
(GO:0051895) 
2 7.98 3.23E-02 
 Vesicle fusion to plasma membrane (GO:0099500) 2 7.98 3.23E-02 
 Regulation of establishment of planar polarity 
involved in neural tube closure (GO:0090178) 
2 7.98 3.23E-02 
 Positive regulation of T cell receptor signaling 
pathway (GO:0050862) 
2 7.98 3.23E-02 
 Synaptic vesicle fusion to presynaptic active zone 
membrane (GO:0031629) 
2 7.98 3.23E-02 
 Monocyte differentiation (GO:0030224) 2 7.98 3.23E-02 
 Response to muscle activity (GO:0014850) 2 7.98 3.23E-02 
 Granulocyte chemotaxis (GO:0071621) 4 3.48 3.25E-02 
 Cellular response to oxygen levels (GO:0071453) 5 2.92 3.30E-02 
 Positive regulation of stress-activated MAPK cascade 
(GO:0032874) 
6 2.59 3.32E-02 
 Maintenance of location (GO:0051235) 7 2.36 3.38E-02 
 Lipid metabolic process (GO:0006629) 29 1.5 3.42E-02 
 Positive regulation of protein modification process 
(GO:0031401) 
29 1.5 3.42E-02 
 Negative regulation of endothelial cell proliferation 
(GO:0001937) 
3 4.49 3.43E-02 
 Dopamine receptor signaling pathway (GO:0007212) 3 4.49 3.43E-02 
 DNA damage response, signal transduction by p53 
class mediator (GO:0030330) 
3 4.49 3.43E-02 
 Positive regulation of glucose import (GO:0046326) 3 4.49 3.43E-02 
 Positive regulation of stress-activated protein kinase 
signaling cascade (GO:0070304) 
6 2.57 3.44E-02 
 Vesicle-mediated transport (GO:0016192) 29 1.5 3.45E-02 
 Cellular lipid metabolic process (GO:0044255) 24 1.57 3.47E-02 
 Leukocyte activation involved in immune response 
(GO:0002366) 
7 2.34 3.49E-02 
 Response to drug (GO:0042493) 17 1.7 3.54E-02 
 Response to mechanical stimulus (GO:0009612) 6 2.54 3.57E-02 
 Central nervous system neuron development 
(GO:0021954) 
4 3.36 3.61E-02 
 Negative regulation of CD4-positive, alpha-beta T cell 
activation (GO:2000515) 
2 7.37 3.67E-02 
 Negative regulation of cell division (GO:0051782) 2 7.37 3.67E-02 
 Maintenance of organelle location (GO:0051657) 2 7.37 3.67E-02 
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 Proton-transporting two-sector atpase complex 
assembly (GO:0070071) 
2 7.37 3.67E-02 
 Regulation of developmental pigmentation 
(GO:0048070) 
2 7.37 3.67E-02 
 Negative regulation of lipid storage (GO:0010888) 2 7.37 3.67E-02 
 Ferric iron transport (GO:0015682) 2 7.37 3.67E-02 
 Venous blood vessel development (GO:0060841) 2 7.37 3.67E-02 
 Positive regulation of T-helper 1 type immune 
response (GO:0002827) 
2 7.37 3.67E-02 
 Negative regulation of adherens junction organization 
(GO:1903392) 
2 7.37 3.67E-02 
 Trivalent inorganic cation transport (GO:0072512) 2 7.37 3.67E-02 
 Neural crest cell migration (GO:0001755) 3 4.35 3.69E-02 
 Adaptive immune response based on somatic 
recombination of immune receptors built from 
immunoglobulin superfamily domains (GO:0002460) 
6 2.52 3.69E-02 
 Vesicle localization (GO:0051648) 7 2.31 3.71E-02 
 Regulation of peptide secretion (GO:0002791) 12 1.96 3.72E-02 
 Maintenance of location in cell (GO:0051651) 5 2.82 3.74E-02 
 Positive regulation of cysteine-type endopeptidase 
activity involved in apoptotic process (GO:0043280) 
5 2.82 3.74E-02 
 Metal ion homeostasis (GO:0055065) 15 1.74 3.75E-02 
 Positive regulation of macromolecule metabolic 
process (GO:0010604) 
67 1.28 3.78E-02 
 Regulation of cellular protein metabolic process 
(GO:0032268) 
58 1.31 3.78E-02 
 Cardiac septum morphogenesis (GO:0060411) 4 3.3 3.80E-02 
 Cellular iron ion homeostasis (GO:0006879) 4 3.3 3.80E-02 
 Leukocyte homeostasis (GO:0001776) 4 3.3 3.80E-02 
 Regulation of response to endoplasmic reticulum 
stress (GO:1905897) 
4 3.3 3.80E-02 
 Apoptotic signaling pathway (GO:0097190) 10 2 3.86E-02 
 Regulation of cell-matrix adhesion (GO:0001952) 5 2.78 3.89E-02 
 Lipid homeostasis (GO:0055088) 5 2.78 3.89E-02 
 Lung alveolus development (GO:0048286) 3 4.23 3.95E-02 
 Developmental pigmentation (GO:0048066) 3 4.23 3.95E-02 
 Positive regulation of protein tyrosine kinase activity 
(GO:0061098) 
3 4.23 3.95E-02 
 Regulation of gliogenesis (GO:0014013) 4 3.25 4.00E-02 
 Outflow tract morphogenesis (GO:0003151) 4 3.25 4.00E-02 
 Negative regulation of cell motility (GO:2000146) 9 2.19 4.03E-02 
 Negative regulation of T cell antigen processing and 
presentation (GO:0002626) 
1 47.9 4.05E-02 
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 Regulation of T cell antigen processing and 
presentation (GO:0002625) 
1 47.9 4.05E-02 
 Negative regulation of asymmetric cell division 
(GO:0045769) 
1 47.9 4.05E-02 
 Positive regulation of leukocyte tethering or rolling 
(GO:1903238) 
1 47.9 4.05E-02 
 Toll-like receptor 10 signaling pathway (GO:0034166) 1 47.9 4.05E-02 
 Establishment or maintenance of cell polarity 
regulating cell shape (GO:0071963) 
1 47.9 4.05E-02 
 Spleen trabecula formation (GO:0060345) 1 47.9 4.05E-02 
 Cellular cadmium ion homeostasis (GO:0006876) 1 47.9 4.05E-02 
 Purine nucleoside bisphosphate catabolic process 
(GO:0034034) 
1 47.9 4.05E-02 
 Ribonucleoside bisphosphate catabolic process 
(GO:0034031) 
1 47.9 4.05E-02 
 T cell antigen processing and presentation 
(GO:0002457) 
1 47.9 4.05E-02 
 Cell proliferation in bone marrow (GO:0071838) 1 47.9 4.05E-02 
 Negative regulation of vasculogenesis (GO:2001213) 1 47.9 4.05E-02 
 Negative regulation of eosinophil activation 
(GO:1902567) 
1 47.9 4.05E-02 
 Negative regulation of CD8-positive, alpha-beta T cell 
activation (GO:2001186) 
1 47.9 4.05E-02 
 MHC class II biosynthetic process (GO:0045342) 1 47.9 4.05E-02 
 VEGF-activated neuropilin signaling pathway 
(GO:0038190) 
1 47.9 4.05E-02 
 Positive regulation of B cell chemotaxis 
(GO:2000538) 
1 47.9 4.05E-02 
 Regulation of B cell chemotaxis (GO:2000537) 1 47.9 4.05E-02 
 VEGF-activated neuropilin signaling pathway 
involved in axon guidance (GO:1902378) 
1 47.9 4.05E-02 
 Interleukin-11-mediated signaling pathway 
(GO:0038154) 
1 47.9 4.05E-02 
 Positive regulation of retinal ganglion cell axon 
guidance (GO:1902336) 
1 47.9 4.05E-02 
 Regulation of copper ion transmembrane transport 
(GO:1902311) 
1 47.9 4.05E-02 
 Positive regulation of hematopoietic stem cell 
migration (GO:2000473) 
1 47.9 4.05E-02 
 Regulation of hematopoietic stem cell migration 
(GO:2000471) 
1 47.9 4.05E-02 
 Positive regulation of astrocyte chemotaxis 
(GO:2000464) 
1 47.9 4.05E-02 
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 Negative regulation of mast cell cytokine production 
(GO:0032764) 
1 47.9 4.05E-02 
 Positive regulation of monocyte extravasation 
(GO:2000439) 
1 47.9 4.05E-02 
 Positive regulation of eosinophil chemotaxis 
(GO:2000424) 
1 47.9 4.05E-02 
 Regulation of eosinophil chemotaxis (GO:2000422) 1 47.9 4.05E-02 
 Positive regulation of hepatocyte growth factor 
receptor signaling pathway (GO:1902204) 
1 47.9 4.05E-02 
 Diaphragm contraction (GO:0002086) 1 47.9 4.05E-02 
 Leukotriene D4 biosynthetic process (GO:1901750) 1 47.9 4.05E-02 
 Leukotriene D4 metabolic process (GO:1901748) 1 47.9 4.05E-02 
 Regulation of glycogen catabolic process 
(GO:0005981) 
1 47.9 4.05E-02 
 Ovarian follicle rupture (GO:0001543) 1 47.9 4.05E-02 
 Interleukin-3 production (GO:0032632) 1 47.9 4.05E-02 
 Peptidyl-serine trans-autophosphorylation 
(GO:1990579) 
1 47.9 4.05E-02 
 Negative regulation of secretion of lysosomal enzymes 
(GO:0090341) 
1 47.9 4.05E-02 
 Positive regulation of peptidyl-cysteine S-nitrosylation 
(GO:2000170) 
1 47.9 4.05E-02 
 Rab protein signal transduction (GO:0032482) 1 47.9 4.05E-02 
 Histone H3-K9 acetylation (GO:0043970) 1 47.9 4.05E-02 
 Positive regulation of immune complex clearance by 
monocytes and macrophages (GO:0090265) 
1 47.9 4.05E-02 
 Regulation of immune complex clearance by 
monocytes and macrophages (GO:0090264) 
1 47.9 4.05E-02 
 Cardiac endothelial to mesenchymal transition 
(GO:0140074) 
1 47.9 4.05E-02 
 Regulation of ER to Golgi vesicle-mediated transport 
by GTP hydrolysis (GO:0090113) 
1 47.9 4.05E-02 
 Positive regulation of calcium ion import across 
plasma membrane (GO:1905665) 
1 47.9 4.05E-02 
 Peptidyl-histidine dephosphorylation (GO:0035971) 1 47.9 4.05E-02 
 Negative regulation of retrograde trans-synaptic 
signaling by neuropeptide (GO:1905433) 
1 47.9 4.05E-02 
 Regulation of retrograde trans-synaptic signaling by 
neuropeptide (GO:1905432) 
1 47.9 4.05E-02 
 Innate vocalization behavior (GO:0098582) 1 47.9 4.05E-02 
 Positive regulation of amyloid precursor protein 
biosynthetic process (GO:0042986) 
1 47.9 4.05E-02 
 Protein trans-autophosphorylation (GO:0036290) 1 47.9 4.05E-02 
 D-serine transport (GO:0042942) 1 47.9 4.05E-02 
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 D-alanine transport (GO:0042941) 1 47.9 4.05E-02 
 mRNA splicing via endonucleolytic cleavage and 
ligation involved in unfolded protein response 
(GO:0030969) 
1 47.9 4.05E-02 
 Negative regulation of G1/S transition of mitotic cell 
cycle by negative regulation of transcription from 
RNA polymerase II promoter (GO:1900477) 
1 47.9 4.05E-02 
 T-helper 17 cell chemotaxis (GO:0035705) 1 47.9 4.05E-02 
 Helper T cell chemotaxis (GO:0035704) 1 47.9 4.05E-02 
 Negative regulation of eosinophil degranulation 
(GO:0043310) 
1 47.9 4.05E-02 
 Pyridoxal 5'-phosphate salvage (GO:0009443) 1 47.9 4.05E-02 
 Negative regulation of short-term neuronal synaptic 
plasticity (GO:0048174) 
1 47.9 4.05E-02 
 mRNA endonucleolytic cleavage involved in unfolded 
protein response (GO:0070055) 
1 47.9 4.05E-02 
 mRNA splicing, via endonucleolytic cleavage and 
ligation (GO:0070054) 
1 47.9 4.05E-02 
 Regulation of granulosa cell apoptotic process 
(GO:1904708) 
1 47.9 4.05E-02 
 Tricarboxylic acid transmembrane transport 
(GO:0035674) 
1 47.9 4.05E-02 
 Positive regulation of protein localization to 
phagocytic vesicle (GO:1905171) 
1 47.9 4.05E-02 
 Regulation of protein localization to phagocytic 
vesicle (GO:1905169) 
1 47.9 4.05E-02 
 Regulation of transcription involved in G2/M 
transition of mitotic cell cycle (GO:0000117) 
1 47.9 4.05E-02 
 Negative regulation of astrocyte activation 
(GO:0061889) 
1 47.9 4.05E-02 
 Vacuolar sequestering (GO:0043181) 1 47.9 4.05E-02 
 Maltose metabolic process (GO:0000023) 1 47.9 4.05E-02 
 Otic placode development (GO:1905040) 1 47.9 4.05E-02 
 Coenzyme A catabolic process (GO:0015938) 1 47.9 4.05E-02 
 Pyrimidine nucleoside transport (GO:0015864) 1 47.9 4.05E-02 
 Ferrous iron export across plasma membrane 
(GO:1903988) 
1 47.9 4.05E-02 
 Negative regulation of microglial cell activation 
(GO:1903979) 
1 47.9 4.05E-02 
 UDP-glucose transmembrane transport (GO:0015786) 1 47.9 4.05E-02 
 Nitrite transport (GO:0015707) 1 47.9 4.05E-02 
 Coreceptor-mediated virion attachment to host cell 
(GO:0046814) 
1 47.9 4.05E-02 
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 Negative regulation of antigen processing and 
presentation of endogenous peptide antigen via MHC 
class I (GO:1904283) 
1 47.9 4.05E-02 
 Regulation of antigen processing and presentation of 
endogenous peptide antigen via MHC class I 
(GO:1904282) 
1 47.9 4.05E-02 
 Positive regulation of glutathione biosynthetic process 
(GO:1903788) 
1 47.9 4.05E-02 
 Regulation of glutathione biosynthetic process 
(GO:1903786) 
1 47.9 4.05E-02 
 Cerebellum vasculature morphogenesis (GO:0061301) 1 47.9 4.05E-02 
 Regulation of COPII vesicle coating (GO:0003400) 1 47.9 4.05E-02 
 Negative regulation of gap junction assembly 
(GO:1903597) 
1 47.9 4.05E-02 
 Propionate metabolic process, methylcitrate cycle 
(GO:0019679) 
1 47.9 4.05E-02 
 Iron cation export (GO:1903414) 1 47.9 4.05E-02 
 Protein localization to early endosome (GO:1902946) 1 47.9 4.05E-02 
 Nucleoside bisphosphate catabolic process 
(GO:0033869) 
1 47.9 4.05E-02 
 Propionate metabolic process (GO:0019541) 1 47.9 4.05E-02 
 Fatty acid derivative metabolic process (GO:1901568) 5 2.75 4.05E-02 
 Coagulation (GO:0050817) 6 2.46 4.09E-02 
 Blood coagulation (GO:0007596) 6 2.46 4.09E-02 
 Negative regulation of immune system process 
(GO:0002683) 
12 1.89 4.09E-02 
 Regulation of developmental process (GO:0050793) 51 1.33 4.10E-02 
 Immune effector process (GO:0002252) 14 1.82 4.10E-02 
 Branching involved in salivary gland morphogenesis 
(GO:0060445) 
2 6.84 4.14E-02 
 Respiratory system process (GO:0003016) 2 6.84 4.14E-02 
 Cell volume homeostasis (GO:0006884) 2 6.84 4.14E-02 
 G-protein coupled acetylcholine receptor signaling 
pathway (GO:0007213) 
2 6.84 4.14E-02 
 DNA replication-independent nucleosome assembly 
(GO:0006336) 
2 6.84 4.14E-02 
 Defense response to protozoan (GO:0042832) 2 6.84 4.14E-02 
 Leukocyte adhesion to vascular endothelial cell 
(GO:0061756) 
2 6.84 4.14E-02 
 Positive regulation of histone deacetylation 
(GO:0031065) 
2 6.84 4.14E-02 
 Regulation of triglyceride biosynthetic process 
(GO:0010866) 
2 6.84 4.14E-02 
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 Negative regulation of alpha-beta T cell differentiation 
(GO:0046639) 
2 6.84 4.14E-02 
 Negative regulation of binding (GO:0051100) 6 2.44 4.22E-02 
 Negative regulation of secretion by cell (GO:1903531) 6 2.44 4.22E-02 
 Regulation of neutrophil migration (GO:1902622) 3 4.11 4.23E-02 
 Calcium ion transport (GO:0006816) 9 2.12 4.32E-02 
 Hemostasis (GO:0007599) 6 2.42 4.36E-02 
 Regulation of protein phosphorylation (GO:0001932) 34 1.42 4.37E-02 
 Negative regulation of multicellular organismal 
process (GO:0051241) 
25 1.5 4.44E-02 
 Cell adhesion (GO:0007155) 20 1.58 4.50E-02 
 Cellular glucose homeostasis (GO:0001678) 3 3.99 4.51E-02 
 Regulation of endothelial cell apoptotic process 
(GO:2000351) 
3 3.99 4.51E-02 
 Cellular response to ammonium ion (GO:0071242) 3 3.99 4.51E-02 
 Lymphocyte chemotaxis (GO:0048247) 3 3.99 4.51E-02 
 Negative regulation of DNA binding (GO:0043392) 3 3.99 4.51E-02 
 Positive regulation of cell killing (GO:0031343) 3 3.99 4.51E-02 
 Positive regulation of glucose transport (GO:0010828) 3 3.99 4.51E-02 
 Post-embryonic development (GO:0009791) 5 2.66 4.55E-02 
 Lymphocyte activation (GO:0046649) 12 1.83 4.58E-02 
 Regulation of protein tyrosine kinase activity 
(GO:0061097) 
4 3.09 4.61E-02 
 Regulation of protein maturation (GO:1903317) 4 3.09 4.61E-02 
 Glycoprotein catabolic process (GO:0006516) 2 6.39 4.63E-02 
 Response to protozoan (GO:0001562) 2 6.39 4.63E-02 
 Regulation of epithelial tube formation (GO:1905276) 2 6.39 4.63E-02 
 Antigen processing and presentation, exogenous lipid 
antigen via MHC class Ib (GO:0048007) 
2 6.39 4.63E-02 
 Antigen processing and presentation of lipid antigen 
via MHC class Ib (GO:0048003) 
2 6.39 4.63E-02 
 DNA replication-independent nucleosome 
organization (GO:0034724) 
2 6.39 4.63E-02 
 Kidney vasculature development (GO:0061440) 2 6.39 4.63E-02 
 Renal system vasculature development (GO:0061437) 2 6.39 4.63E-02 
 Regulation of T-helper 1 type immune response 
(GO:0002825) 
2 6.39 4.63E-02 
 Peptidyl-tyrosine phosphorylation (GO:0018108) 6 2.38 4.65E-02 
 Negative regulation of MAPK cascade (GO:0043409) 6 2.36 4.80E-02 
 Regulation of leukocyte mediated immunity 
(GO:0002703) 
6 2.36 4.80E-02 
 Sprouting angiogenesis (GO:0002040) 3 3.88 4.81E-02 
 Positive regulation of wound healing (GO:0090303) 3 3.88 4.81E-02 
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 Table A.2 continued      
 GO biological process complete #genes FE P-value 
 Regulation of transcription from RNA polymerase II 
promoter in response to stress (GO:0043618) 
3 3.88 4.81E-02 
 Oligosaccharide metabolic process (GO:0009311) 3 3.88 4.81E-02 
 Positive regulation of response to biotic stimulus 
(GO:0002833) 
3 3.88 4.81E-02 
 Positive regulation of cysteine-type endopeptidase 
activity (GO:2001056) 
5 2.6 4.90E-02 
 Cellular response to leukemia inhibitory factor 
(GO:1990830) 
5 2.6 4.90E-02 
 Response to leukemia inhibitory factor (GO:1990823) 5 2.6 4.90E-02 
 Cellular response to metal ion (GO:0071248) 5 2.6 4.90E-02 
#genes: number of genes associated with the GO term in the list of differentially expressed 
genes (DEG, q-value < 0.05) 
FE: Fold Enrichment  
 
 
 
 
